<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Rivastigmine for Alzheimer's disease - Birks, JS - 2015 | Cochrane Library</title> <meta content="Rivastigmine for Alzheimer's disease - Birks, JS - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Rivastigmine for Alzheimer's disease - Birks, JS - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001191.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Rivastigmine for Alzheimer's disease" name="citation_title"/> <meta content="Jacqueline S Birks" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="jacqueline.birks@csm.ox.ac.uk" name="citation_author_email"/> <meta content="Lee‐Yee Chong" name="citation_author"/> <meta content="UK Cochrane Centre" name="citation_author_institution"/> <meta content="John Grimley Evans&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD001191.pub4" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/09/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alzheimer Disease [*drug therapy]; Caregivers [psychology]; Cholinesterase Inhibitors [*administration &amp; dosage, adverse effects]; Cognition Disorders [drug therapy]; Drug Administration Schedule; Phenylcarbamates [*administration &amp; dosage, adverse effects]; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001191.pub4&amp;doi=10.1002/14651858.CD001191.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="EBp84H4P";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001191\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001191\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","fa","ja"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001191.pub4",title:"Rivastigmine for Alzheimer\u0027s disease",firstPublishedDate:"Sep 22, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001191.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001191.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001191.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001191.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001191.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001191.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001191.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001191.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001191.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001191.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9189 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001191.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-sec-0122"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-sec-0020"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-sec-0021"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-sec-0114"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/appendices#CD001191-sec-0127"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/table_n/CD001191StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/table_n/CD001191StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Rivastigmine for Alzheimer's disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/information#CD001191-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Jacqueline S Birks</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/information#CD001191-cr-0003">Lee‐Yee Chong</a></li> <li class="author custom-tooltip" title="Deceased"><a href="/cdsr/doi/10.1002/14651858.CD001191.pub4/information#CD001191-cr-0004">John Grimley Evans</a><sup>a</sup></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/information/en#CD001191-sec-0133">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 September 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001191.pub4">https://doi.org/10.1002/14651858.CD001191.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001191-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001191-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001191-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001191-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001191-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001191-abs-0001" lang="en"> <section id="CD001191-sec-0001"> <h3 class="title" id="CD001191-sec-0001">Background</h3> <p>Alzheimer's disease is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by the use of cholinesterase inhibitors to delay the breakdown of acetylcholine released into synaptic clefts. Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity. Other cholinesterase inhibitors, including rivastigmine, with superior properties in terms of specificity of action and lower risk of adverse effects have since been introduced. Rivastigmine has received approval for use in 60 countries including all member states of the European Union and the USA. </p> </section> <section id="CD001191-sec-0002"> <h3 class="title" id="CD001191-sec-0002">Objectives</h3> <p>To determine the clinical efficacy and safety of rivastigmine for patients with dementia of Alzheimer's type. </p> </section> <section id="CD001191-sec-0003"> <h3 class="title" id="CD001191-sec-0003">Search methods</h3> <p>We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group Specialized Register, on 2 March 2015 using the terms: Rivastigmine OR  exelon OR ENA OR "SDZ ENA 713". ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases (Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS), numerous trial registries and grey literature sources. </p> </section> <section id="CD001191-sec-0004"> <h3 class="title" id="CD001191-sec-0004">Selection criteria</h3> <p>We included all unconfounded, double‐blind, randomised, controlled trials in which treatment with rivastigmine was administered to patients with dementia of the Alzheimer's type for 12 weeks or more and its effects compared with those of placebo in a parallel group of patients, or where two formulations of rivastigmine were compared. </p> </section> <section id="CD001191-sec-0005"> <h3 class="title" id="CD001191-sec-0005">Data collection and analysis</h3> <p>One review author (JSB) applied the study selection criteria, assessed the quality of studies and extracted data. </p> </section> <section id="CD001191-sec-0006"> <h3 class="title" id="CD001191-sec-0006">Main results</h3> <p>A total of 13 trials met the inclusion criteria of the review. The trials had a duration of between 12 and 52 weeks. The older trials tested a capsule form with a dose of up to 12 mg/day. Trials reported since 2007 have tested continuous dose transdermal patch formulations delivering 4.6, 9.5 and 17.7 mg/day. </p> <p>Our main analysis compared the safety and efficacy of rivastigmine 6 to 12 mg/day orally or 9.5 mg/day transdermally with placebo. </p> <p>Seven trials contributed data from 3450 patients to this analysis. Data from another two studies were not included because of a lack of information and methodological concerns. All the included trials were multicentre trials and recruited patients with mild to moderate Alzheimer's disease with a mean age of about 75 years. All had low risk of bias for randomisation and allocation but the risk of bias due to attrition was unclear in four studies, low in one study and high in two studies. </p> <p>After 26 weeks of treatment rivastigmine compared to placebo was associated with better outcomes for cognitive function measured with the Alzheimer's Disease Assessment Scale‐Cognitive (ADAS‐Cog) score (mean difference (MD) ‐1.79; 95% confidence interval (CI) ‐2.21 to ‐1.37, n = 3232, 6 studies) and the Mini‐Mental State Examination (MMSE) score (MD 0.74; 95% CI 0.52 to 0.97, n = 3205, 6 studies), activities of daily living (SMD 0.20; 95% CI 0.13 to 0.27, n = 3230, 6 studies) and clinician rated global impression of changes, with a smaller proportion of patients treated with rivastigmine experiencing no change or a deterioration (OR 0.68; 95% CI 0.58 to 0.80, n = 3338, 7 studies). </p> <p>Three studies reported behavioural change, and there were no differences compared to placebo (standardised mean difference (SMD) ‐0.04; 95% CI ‐0.14 to 0.06, n = 1529, 3 studies). Only one study measured the impact on caregivers using the Neuropsychiatric Inventory‐Caregiver Distress (NPI‐D) scale and this found no difference between the groups (MD 0.10; 95% CI ‐0.91 to 1.11, n = 529, 1 study). Overall, participants who received rivastigmine were about twice as likely to withdraw from the trials (odds ratio (OR) 2.01, 95% CI 1.71 to 2.37, n = 3569, 7 studies) or to experience an adverse event during the trials (OR 2.16, 95% CI 1.82 to 2.57, n = 3587, 7 studies). </p> </section> <section id="CD001191-sec-0007"> <h3 class="title" id="CD001191-sec-0007">Authors' conclusions</h3> <p>Rivastigmine (6 to 12 mg daily orally or 9.5 mg daily transdermally) appears to be beneficial for people with mild to moderate Alzheimer's disease. In comparisons with placebo, better outcomes were observed for rate of decline of cognitive function and activities of daily living, although the effects were small and of uncertain clinical importance. There was also a benefit from rivastigmine on the outcome of clinician's global assessment. There were no differences between the rivastigmine group and placebo group in behavioural change or impact on carers. At these doses the transdermal patch may have fewer side effects than the capsules but has comparable efficacy. The quality of evidence is only moderate for all of the outcomes reviewed because of a risk of bias due to dropouts. All the studies with usable data were industry funded or sponsored. This review has not examined economic data. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001191-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001191-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001191-abs-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001191-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001191-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD001191-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001191-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001191-abs-0003" lang="en"> <h3>Rivastigmine for people with Alzheimer's disease</h3> <p><b>Review question</b> </p> <p>We reviewed evidence comparing the effectiveness and safety of rivastigmine with placebo in people with Alzheimer's disease.<br/> <br/> <b>Background</b> </p> <p>Alzheimer's disease is the commonest cause of dementia affecting older people. As the disease progresses, people lose the ability to remember, communicate, think clearly and perform the usual daily activities. Their behaviour or personality may also change. In severe Alzheimer's disease, the patients lose the ability to care for themselves and require full time care. </p> <p>Currently, there is no cure available for Alzheimer's disease, but a few pharmacological interventions are available to alleviate symptoms. </p> <p>The symptoms are caused by the loss of a type of nerve cell in the brain called cholinergic neurons. Rivastigmine, an acetylcholinesterase inhibitor, works by increasing the levels of a brain chemical called acetylcholine which allows the nerve cells to communicate. This may improve the symptoms of dementia. Rivastigmine can be taken orally, either as capsules or a liquid, or by applying a patch on the skin. Its effectiveness in improving the symptoms of Alzheimer's disease and safety were evaluated in this review. </p> <p><b>Study characteristics</b> </p> <p>This review included double‐blinded randomised controlled trials, and the evidence was searched for up to March 2015 using the standard Cochrane methods. The review included studies conducted for at least 12 weeks that compared the safety and effectiveness of rivastigmine compared with placebo. Thirteen studies that met these criteria were found. Most of these studies involved people with mild to moderate Alzheimer's disease with an average age of around 75 years. </p> <p><b>Key results</b> </p> <p>Results from seven trials showed that patients on rivastigmine (6 to 12 mg/day by mouth, or 9.5 mg/day by skin patch) were better for three outcomes than those on placebo, after six months of treatment. The differences were quite small for cognitive function (2 points, using the ADAS‐Cog which has a range of 70 points) and activities of daily living (standardised mean difference (SMD) of 0.20, which is considered a small effect). Patients on rivastigmine were more likely to show overall improvement compared with those on placebo (odds ratio of 1.47, 95% confidence interval (CI) of 1.25 to 1.72) . However, there was no difference for behavioural changes (reported by three trials) or impact on carers (reported by one trial). Patients on rivastigmine were also about twice as likely to experience adverse events, although this risk might have been slightly less for patients using patches compared with capsules. It was possible that certain types of adverse events were less in people using patches than taking capsules (nausea, vomiting, weight loss, dizziness). </p> <p>In summary, rivastigmine may be of benefit to people with Alzheimer's disease. It is possible that the using a patch is associated with reduced side effects compared to using oral capsules. </p> <p><b>Quality of evidence</b> </p> <p>The quality of the evidence for most of the outcomes reviewed was moderate. The main factors affecting our confidence in the results included relatively high number of patients dropping out in some of the trials (the rates of dropout in the rivastigmine arms were higher). There were also concerns about the applicability of the evidence for the long term treatment of Alzheimer's disease since data from double‐blinded randomised controlled trials were only available for up to 12 months. All the data included in the main analysis of this review came from studies either sponsored or funded by the drug manufacturer (Novartis Pharma). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001191-sec-0122" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001191-sec-0122"></div> <h3 class="title" id="CD001191-sec-0123">Implications for practice</h3> <section id="CD001191-sec-0123"> <p>Use of rivastigmine in doses of 6 to 12 mg daily is associated with statistically significant benefits in terms of cognitive function. Benefits are also seen in the activities of daily living and clinician rated global impression scale ratings, which suggests that they may be of clinical as well as statistical significance. At lower doses (4 mg or less total daily dose) differences were in the same direction and were significant for cognitive function. Significant differences in the CIBIC‐Plus were seen at 26 weeks but not earlier. The 10 cm<sup>2</sup> (9.5 mg/day) patch has been tested in two placebo controlled trials and shows similar benefits to the 6 to 12 mg oral dose. One double‐blind placebo controlled study of longer than 26 weeks is included in this review, but the data were not included in the meta‐analyses due to concerns about the study. This present review has not examined economic data. </p> <p>Side effects observed were predictably related to the cholinergic actions of the drug. They may be related to the pharmacokinetics of the drug and merit further study. Three sizes of transdermal patch have been tested in two trials, and there is evidence that the 9.5 mg/day patch is associated with fewer side effects than the capsules or the higher dose larger patches and has comparable efficacy to all three. </p> </section> <h3 class="title" id="CD001191-sec-0124">Implications for research</h3> <section id="CD001191-sec-0124"> <p>Longer term studies with a focus on clinically significant endpoints need to be linked to economic analyses to generate information on cost‐utility. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001191-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001191-sec-0015"></div> <div class="table" id="CD001191-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Rivastigmine compared to placebo for Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm<sup>2</sup> (9.8 mg/day) patch) compared to placebo for Alzheimer's disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Alzheimer's disease, mild to moderate<br/> <b>Settings:</b> multicentre, mostly in Europe or United States<br/> <b>Intervention:</b> rivastigmine (capsules 6 to 12 mg/day in 2 divided doses or 10 cm<sup>2</sup> patch) for 24 to 26 weeks<br/> <b>Comparison:</b> placebo for 24 to 26 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Rivastigmine (capsules 6 to 12 mg/day b.i.d. or 10 cm<sup>2</sup> patch)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 26 weeks using ADAS‐Cog)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the rivastigmine group was <b>1.79 lower</b> (2.21 to 1.37 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3232<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog score has a maximum of 70 points, the lower score of the rivastigmine group indicates greater improvement </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognitive function</b> </p> <p>(change from baseline at 26 weeks using MMSE)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score in the rivastigmine group was <b>0.74 higher</b> (0.52 to 0.97 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3205 (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE has a maximum score of 30 points, a lower score indicates greater impairment. treatment effect was in favour of rivastigmine </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Activities of daily living</b> </p> <p>(change from baseline at 26 weeks measured using various scales)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the rivastigmine group was <b>0.2 standard deviations higher</b><br/> (0.13 to 0.27 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3230<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.2 (0.13 to 0.27)</p> <p>A SMD of 0.2 is considered a small effect size.</p> <p>Treatment effect in favour of rivastigmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Physician rated global impression tests</b> (no change or worse compared with baseline, measured using Global Impression of Change at 26 weeks) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>810 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>744 per 1000</b> (712 to 773) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.68</b> <br/> (0.58 to 0.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3338<br/> (7 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment effect was in favour of rivastigmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behavioural symptoms</p> <p>(change from baseline at 26 weeks measured using various scales)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the rivastigmine group was<br/> <b>0.04 standard deviations lower</b> (0.14 lower to 0.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1529<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.04 (‐0.14 to 0.06)</p> <p>A SMD of 0.2 is considered a small effect size. The size of this SMD and its small confidence interval suggests that there is no difference between the two groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> (as measured by withdrawals from trials before end of treatment at 26 weeks) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>149 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b> (230 to 293) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.01</b> (1.71, 2.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3569<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals significantly more frequent in rivastigmine group compared with placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of adverse events</b> (at least one adverse event by 26 weeks) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>761 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>870 per 1000</b> (850 to 888) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.14</b> </p> <p>(1.80 to 2.53)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3587<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events significantly more frequent in rivastigmine group compared with placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life of patients or carers</b> (measured using NPI‐D carer distress scale (change from baseline at 24 weeks) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the rivastigmine group was <b>0.1 higher</b> (0.91 lower to 1.11 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>529<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The size of this MD and its small confidence interval suggests that there is no difference between the two groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>assumed risk</b> used the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Confidence in estimate of effect lowered due to relatively high dropout rates across studies, which are higher in the treatment group. The ITT analysis in these studies used LOCF (last observed carried forward) imputations. In addition, results are available up to only 26 weeks, longer term data would be more applicable. </p> <p><sup>2</sup> There was high heterogeneity the ADAS‐Cog outcome due to B352, which had high dropout rates and showed a difference of 3.8 points, compared to 1.2 to 1.6 points for the other studies. However, evidence not further downgraded; removal of this study from the analysis will only result in a small change of estimate by about 0.35 points.<br/> <sup>3</sup> Three studies (<a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>; <a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a>; <a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a>) reported a scale measuring behavioural disturbance.<br/> <sup>4</sup> The protocol for most studies had some measures related to quality of life or impact on carers, but only one study reported this (<a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001191-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001191-sec-0016"></div> <section id="CD001191-sec-0017"> <h3 class="title" id="CD001191-sec-0017">Description of the condition</h3> <p>Alzheimer's disease (AD), alone or in combination with other brain conditions, is the commonest cause of dementia affecting older people. It is associated with the loss of cholinergic neurons in parts of the brain subserving aspects of memory. As the disease progresses, people lose the ability to remember, communicate, think clearly and perform their usual daily activities. Their behaviour or personality may also change. In severe AD, people lose the ability to care for themselves and require full time care. </p> <p>Currently there is no cure available for AD, but a few pharmacological interventions are available to alleviate symptoms. </p> </section> <section id="CD001191-sec-0018"> <h3 class="title" id="CD001191-sec-0018">Description of the intervention</h3> <p>Acetylcholinesterase inhibitors, such as rivastigmine, delay the breakdown of acetylcholine released into synaptic clefts and may enhance cholinergic neurotransmission. </p> <p>Tacrine, the first of the acetylcholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant disadvantages, including low oral bioavailability and metabolism involving hepatic microsomal enzymes with a consequent risk of interactions with other drugs. Tacrine was also associated with adverse effects including hepatotoxicity. Several other acetylcholinesterase inhibitors, including rivastigmine, galantamine, and donepezil, have now been introduced. They are believed to have superior properties in terms of specificity of action and low incidence of adverse effects. </p> <p>Rivastigmine is a 'pseudo‐irreversible' inhibitor of acetyl and butyrylcholinesterases with a phenylcarbamate structure, the metabolism of which is almost totally independent of the hepatic cytochrome P450 system. After binding to cholinesterase, the carbamate portion of rivastigmine is slowly hydrolysed, cleaved, conjugated to a sulphate and excreted. Rivastigmine has an oral bioavailability of 0.355 and low (40%) binding to plasma proteins. Its elimination half‐life is around two hours. Its disposition is essentially unaltered in patients with renal or hepatic impairment (<a href="./references#CD001191-bbs2-0083" title="JannMW . Rivastigmine, a new‐generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy2000;20:1‐12. ">Jann 2000</a>) and the risk of interactions with other drugs is low (<a href="./references#CD001191-bbs2-0075" title="GrossbergGT , StahelinHB , MessinaJC , AnandR , VeachJ . Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty‐two classes of medications. International Journal of Geriatric Psychiatry2000;15:242‐7. ">Grossberg 2000</a>). This is of particular relevance for elderly patients with AD, some of whom may also need medications for other conditions. The drug is selective both to the central nervous system (CNS) and within it. In studies in human volunteers the inhibition of central acetylcholinesterase was substantially greater than the inhibition of peripheral acetylcholinesterase or butyrylcholinesterase (<a href="./references#CD001191-bbs2-0084" title="KennedyJS , PolinskyRJ , JohnsonB , LoosenP , EnzA , LaplancheR , et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. Journal of Clinical Psychopharmacology1999;19:513‐21. ">Kennedy 1999</a>). Evidence from animal studies suggests that rivastigmine is a more potent inhibitor of acetylcholinesterase in the cortex and hippocampus, the brain regions most affected by AD (<a href="./references#CD001191-bbs2-0088" title="PolinskyRJ . Clinical pharmacology of rivastigmine: A new‐generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clinical Therapeutics1998;20(4):634‐46. ">Polinsky 1998</a>). Rivastigmine also preferentially inhibits the G1 enzymatic form of acetylcholinesterase, which predominates in the brains of patients with AD (<a href="./references#CD001191-bbs2-0088" title="PolinskyRJ . Clinical pharmacology of rivastigmine: A new‐generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clinical Therapeutics1998;20(4):634‐46. ">Polinsky 1998</a>). Rivastigmine is long‐acting and readily penetrates the CNS after parenteral or oral administration. The duration of cholinesterase inhibition by rivastigmine is approximately 10 hours. </p> <p>Rivastigmine can be administered orally as capsules or liquid or from a transdermal patch, which has been developed more recently. Based on pharmacokinetic principles, the transdermal patch form was postulated to have advantages over the oral form. Adherence was expected to be improved by once daily dosing. Tolerance was also expected to be improved as the patch delivers a more steady concentration of rivastigmine to the body and has a lower equivalent dose to the oral form (9.5 mg as a transdermal patch is equivalent to 12 mg daily in the oral form). </p> </section> <section id="CD001191-sec-0019"> <h3 class="title" id="CD001191-sec-0019">Why it is important to do this review</h3> <p>Large multicentre trials have been completed in the USA, Canada, Europe, Australia and South Africa. Rivastigmine has received approval for use in 60 countries including all the member states of the European Union and in the USA, where it received approval from the Food and Drugs Administration (FDA) in April 2000. It is important to assess the safety and efficacy of this intervention in a systematic review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001191-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001191-sec-0020"></div> <p> <ol id="CD001191-list-0001"> <li> <p>To determine the clinical efficacy and safety of rivastigmine for patients with dementia of Alzheimer's type </p> </li> <li> <p>To compare the efficacy and safety of the oral and transdermal formulations of rivastigmine</p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001191-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001191-sec-0021"></div> <section id="CD001191-sec-0022"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001191-sec-0023"> <h4 class="title">Types of studies</h4> <p>We included double‐blind, randomised controlled trials in which rivastigmine was administered for 12 weeks or longer and compared with placebo; or rivastigmine patches were compared with rivastigmine capsules. Trials in which the allocation to treatment was not randomised, or in which treatment allocation was not concealed, were excluded. This was because prior knowledge of treatment allocation may lead to biased allocation of patients (<a href="./references#CD001191-bbs2-0098" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273:408‐12. ">Schulz 1995</a>). </p> </section> <section id="CD001191-sec-0024"> <h4 class="title">Types of participants</h4> <p>The patients in trials to be included were diagnosed with probable AD according to internationally accepted criteria such as the Diagnostic and Statistical Manual of Mental Disorders DSM‐IV (<a href="./references#CD001191-bbs2-0067" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Press, 1994. ">DSM IV</a>) and National Institute of Neurological and Communicative Disorders and Stroke‐Alzheimer's Disease and Related Disorders Association (NINCDS‐ADRDA) criteria (<a href="./references#CD001191-bbs2-0085" title="McKhannG , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology1984;34:939‐44. ">McKhann 1984</a>). </p> </section> <section id="CD001191-sec-0025"> <h4 class="title">Types of interventions</h4> <section id="CD001191-sec-0026"> <h5 class="title">Objective 1</h5> <p>Intervention: rivastigmine given at any dose, using any method of administration</p> <p>Comparison: placebo</p> </section> <section id="CD001191-sec-0027"> <h5 class="title">Objective 2</h5> <p>Intervention: rivastigmine patches at the manufacturer's recommended dose</p> <p>Comparison: rivastigmine capsules at the manufacturer's recommended dose</p> </section> </section> <section id="CD001191-sec-0028"> <h4 class="title">Types of outcome measures</h4> <p>In the original protocol and during the review, we looked for all the following outcomes:</p> <p> <ol id="CD001191-list-0002"> <li> <p>cognitive function (as measured by psychometric tests);</p> </li> <li> <p>functional performance;</p> </li> <li> <p>global impression;</p> </li> <li> <p>behavioural disturbance;</p> </li> <li> <p>acceptability of treatment as measured by withdrawal from trials;</p> </li> <li> <p>incidence of adverse effects;</p> </li> <li> <p>effect on carers;</p> </li> <li> <p>death;</p> </li> <li> <p>institutionalisation rates;</p> </li> <li> <p>quality of life;</p> </li> <li> <p>dependency.</p> </li> </ol> </p> </section> </section> <section id="CD001191-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001191-sec-0030"> <h4 class="title">Electronic searches</h4> <p>We searched ALOIS (<a href="http://www.medicine.ox.ac.uk/alois" target="_blank">www.medicine.ox.ac.uk/alois</a>), the Cochrane Dementia and Cognitive Improvement Group Specialized Register, on 2 March 2015. The search terms used were: Rivastigmine OR  exelon OR ENA OR "SDZ ENA 713". </p> <p>ALOIS is maintained by the Trials Search Co‐ordinator of the Cochrane Dementia and Cognitive Improvement Group and contains studies in the areas of dementia prevention, dementia treatment and cognitive enhancement in healthy people. The studies are identified from:   </p> <p> <ol id="CD001191-list-0003"> <li> <p>monthly searches of a number of the major healthcare databases, MEDLINE, EMBASE, CINAHL, PsycINFO and LILACS; </p> </li> <li> <p>monthly searches of a number of the trial registers, ISRCTN, UMIN (Japan's Trial Register), the World Health Organization (WHO) Clinical Trials Registry Platform portal (which covers ClinicalTrials.gov, ISRCTN, the Chinese Clinical Trials Register, the German Clinical Trials Register, the Iranian Registry of Clinical Trials, and the Netherlands National Trials Register, plus others); </p> </li> <li> <p>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library; </p> </li> <li> <p>six‐monthly searches of a number of grey literature sources, ISI Web of Knowledge Conference Proceedings, Index to Theses, Australasian Digital Theses. </p> </li> </ol> </p> <p>To view a list of all sources searched for ALOIS see <a href="http://www.medicine.ox.ac.uk/alois/content/about-alois" target="_blank">About ALOIS</a> on the ALOIS website. </p> <p>Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, CENTRAL and conference proceedings can be viewed in the ‘methods used in reviews’ section within the editorial information about the <a href="http://mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html" target="_blank">Dementia and Cognitive Improvement Group</a>. </p> <p>Additional searches were performed in many of the sources listed above to cover the timeframe from the last searches performed for ALOIS to ensure that the search for the review was as up‐to‐date and as comprehensive as possible. The search strategies used can be seen in <a href="./appendices#CD001191-sec-0128">Appendix 1</a>. </p> <p>The latest search for this review (March 2015) retrieved a total of 17 results for consideration. </p> </section> <section id="CD001191-sec-0031"> <h4 class="title">Searching other resources</h4> <p>In addition, the search engines Copernic and Google were used to find evidence of unreported or unpublished trials using the word rivastigmine and its synonyms. Novartis websites, the Food and Drug Administration (FDA), European Medicines Agency (EMEA) and National Institute for Health and Care Excellence (NICE) websites were searched for data and evidence of trials. </p> <p>1. Reference searching<br/> The references of all identified studies were inspected for more studies. </p> <p>2. Pharmaceutical companies<br/> Novartis, the developer of rivastigmine, was contacted for information about any unpublished and published trials. </p> </section> </section> <section id="CD001191-sec-0032"> <h3 class="title" id="CD001191-sec-0032">Data collection and analysis</h3> <section id="CD001191-sec-0033"> <h4 class="title">Selection of studies</h4> <p>Irrelevant citations were discarded by a review of the title of the publication and its abstract. In the presence of any suggestion that the article could possibly be relevant, it was retrieved in full for further assessment. In the later versions of the review, one review author (JSB) selected the trials for inclusion in the review from the culled citation list. </p> <p>There were multiple publications for most of the industry sponsored trials, often reporting different aspects (outcomes) of the studies or different lengths of follow up. </p> </section> <section id="CD001191-sec-0034"> <h4 class="title">Data extraction and management</h4> <p>Data were extracted from the published reports in journals and unpublished company reports using data collection forms. One review author (JSB) extracted information from the reports of each study. </p> <p>In addition to extracting pre‐specified information about study characteristics and aspects of methodology relevant to risk of bias, the following summary statistics, required for each trial and each outcome, were extracted. </p> <p> <ul id="CD001191-list-0004"> <li> <p>For continuous data, mean change from baseline, the standard deviation, and the number of patients for each treatment group at each assessment. Where changes from baseline were not reported, the mean, standard deviation and number of patients for each treatment group at each time point were extracted, if available. </p> </li> <li> <p>For binary data, the numbers in each treatment group and the numbers experiencing the outcome of interest were sought. </p> </li> <li> <p>For ordinal variables which can be approximated to continuous variables, the main outcomes of interest were the assessment score at the time point being considered and the change from baseline (i.e. pre‐randomisation or at randomisation) at this time point. For some binary and ordinal outcomes the endpoint category relative to the baseline category was the outcome of interest. For other categorical outcomes, such as the Clinical Global Impression of Change (CIBIC‐Plus), the endpoint itself was of clinical relevance as all patients had begun, by definition, at the same baseline score. </p> </li> </ul> </p> <p>The baseline assessment score was the latest available score, no longer than two months prior to the randomisation. Studies may have included a titration period prior to the randomisation phase of the study. Data from any open follow‐on phase, after the randomised phase, were not used to assess safety or efficacy. </p> <p>For each outcome measure, data were sought on every patient assessed. To allow an intention‐to‐treat analysis (ITT), the data were sought irrespective of compliance and whether or not the patient was subsequently deemed ineligible or otherwise excluded from treatment or follow up. If ITT data were not available, an analysis of patients who completed treatment was conducted. </p> </section> <section id="CD001191-sec-0035"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The risk of bias assessment was conducted using the standard recommended approach for assessing the risk of bias in studies included in Cochrane reviews. The Cochrane Collaboration risk of bias tool is available in RevMan 5.2 and assesses the following domains: </p> <p> <ul id="CD001191-list-0005"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcomes assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>'other bias'.</p> </li> </ul> </p> <p>We made a judgement about the risk of bias in each domain, assigning it to one of three categories: 'high', 'low' or 'unclear' risk of bias. These assessments were based on the criteria for making judgements that are listed in section 8.5 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. The criteria focus on whether the risk is of importance (that is whether the presence of the risk could have an important impact on the results or the outcomes of the trial) rather than whether a risk of bias is present or not (<a href="./references#CD001191-bbs2-0080" title="Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. In: HigginsJPT , GreenS editor(s). [updated March 2011]. Available from www.cochrane‐handbook.org.: The Cochrane Collaboration, 2011. ">Higgins 2011</a>). The levels of risk may be different for different outcomes and this was considered during the assessment. </p> <p>If insufficient detail was reported to make a judgement, this was usually considered as an ‘unclear' risk of bias. An ‘unclear’ judgement was also used in situations where it was clear what happened in the study but its likely impact on the study results was not known. </p> </section> <section id="CD001191-sec-0036"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (where the outcome of interest was either present or absent), the estimate of treatment effect of the intervention was expressed as the Peto odds ratio (OR) together with the 95% confidence interval (CI). </p> <p>For continuous data the measure of treatment effect was the mean difference (MD) or the standardised mean difference (SMD). </p> </section> <section id="CD001191-sec-0037"> <h4 class="title">Unit of analysis issues</h4> <p>The review only included parallel‐group, double‐blinded randomised controlled trials (RCTs), with individual patients randomised. No unit of analysis issues were expected or encountered. </p> </section> <section id="CD001191-sec-0038"> <h4 class="title">Dealing with missing data</h4> <p>Where data were missing from the published report of a trial, the authors or the study sponsors were contacted to obtain the data and to clarify any uncertainty. </p> <p>We made no attempts at data imputation, except for the estimation of standard deviations for continuous data using the methods detailed in section 7.7.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001191-bbs2-0080" title="Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. In: HigginsJPT , GreenS editor(s). [updated March 2011]. Available from www.cochrane‐handbook.org.: The Cochrane Collaboration, 2011. ">Higgins 2011</a>). </p> <p>Where possible we reported ITT analyses. We conducted sensitivity analyses to compare methods of dealing with missing data. </p> </section> <section id="CD001191-sec-0039"> <h4 class="title">Assessment of heterogeneity</h4> <p>Potential differences between the included studies in the types of participants, interventions or control used were assessed before pooling data. No subgroup analyses were planned. </p> <p>We assessed heterogeneity between studies using the Chi<sup>2</sup> test (with a significance level set at P &lt; 0.10) and the I<sup>2</sup> statistic, which calculates the percentage of variability due to heterogeneity rather than to chance, with I<sup>2</sup> values over 50% suggesting substantial heterogeneity (<a href="./references#CD001191-bbs2-0080" title="Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. In: HigginsJPT , GreenS editor(s). [updated March 2011]. Available from www.cochrane‐handbook.org.: The Cochrane Collaboration, 2011. ">Higgins 2011</a>). </p> </section> <section id="CD001191-sec-0040"> <h4 class="title">Assessment of reporting biases</h4> <p>Outcomes reported in a trial were compared with the protocol, whenever possible, to examine whether all of the study's pre‐specified outcomes that were of interest to the review had been reported. </p> </section> <section id="CD001191-sec-0041"> <h4 class="title">Data synthesis</h4> <p>For ordinal variables, such as psychometric test scores, functional and quality of life scales, where there are a large number of possible scores, the measure was treated as continuous and the mean difference or the SMD was calculated. </p> <p>For ordinal variables with only a small number of possible values, such as the Clinical Global Impression of Change, the data were reduced to a binary variable. The two classes were improvement compared with no change or worse. For all binary variables the Peto method of the typical OR was used. </p> <p>The duration of the trials varied between 12 weeks and 1 year. Separate meta‐analyses were conducted for endpoints of 12 weeks, 24 to 26 weeks and 52 weeks. Some trials contributed data to more than one meta‐analysis if multiple assessments had been done. </p> <p>A weighted estimate of the typical treatment effect across trials was calculated. Overall estimates of the treatment difference are presented. In all cases the overall estimate from a fixed‐effect model was presented. </p> </section> <section id="CD001191-sec-0042"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Heterogeneity were examined both visually and using the I<sup>2</sup> statistic. Where there was evidence of heterogeneity of the treatment effect between trials then sensitivity analyses were conducted, where only homogeneous results were pooled. </p> <p>There were no pre‐identified subgroups for subgroup analysis.</p> </section> <section id="CD001191-sec-0043"> <h4 class="title">Sensitivity analysis</h4> <p>This review sought to analyse data using ITT data whenever possible. Some studies reported both an ITT analysis that included all patients randomised and a per protocol analysis. The ITT analysis results reported in studies often involved data imputation techniques such as the last observation carried forward (LOCF) for patients who did not complete the study. The impact of different ways of dealing with missing data were investigated using a sensitivity analysis of as observed, ITT and per protocol analyses. These results were tabulated and any important discrepancies discussed. </p> <section id="CD001191-sec-0044"> <h5 class="title">Summary of findings table</h5> <p>We summarised the data on the efficacy and safety of the currently recommended dose of rivastigmine (6 to 12 mg/day orally or 9.5 mg/day transdermally) in the summary of findings table using GRADE methods (<a href="./references#CD001191-bbs2-0077" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , SchunemannHJ . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924. ">Guyatt 2008</a>) to assess the overall quality of the evidence. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001191-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001191-sec-0045"></div> <section id="CD001191-sec-0046"> <h3 class="title">Description of studies</h3> <section id="CD001191-sec-0047"> <h4 class="title">Results of the search</h4> <p>The updated searches performed in 2011, 2013, 2014 and 2015 retrieved a total of 112 references. The full texts of 42 references were read and, of these, 10 were of studies that could be included or additional reports of studies already included, and 32 were of studies that were excluded. </p> </section> <section id="CD001191-sec-0048"> <h4 class="title">Included studies</h4> <p>The characteristics of the 13 included trials are summarised in <a href="./references#CD001191-sec-0142" title="">Characteristics of included studies</a>. </p> <section id="CD001191-sec-0049"> <h5 class="title">Design, participants, samples sizes and setting</h5> <p>Important details of study design (number of participants, duration of follow up, mean Mini‐Mental State Examination (MMSE) of participants at baseline and description of interventions) are summarised in <a href="#CD001191-tbl-0002">Table 1</a> and the objectives of the trials in <a href="#CD001191-tbl-0003">Table 2</a>. </p> <div class="table" id="CD001191-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of the included studies at baseline</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% males</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean MMSE (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of centres</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment groups</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Oral (different doses versus placebo )</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0001" title="AgidY , Dubois B on behalf of the International Rivastigmine Investigators, AnandR , GharabawiG . Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutic Research1998;59(12):837‐45. AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ">B103</a> </p> <p>(Phase II)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0006"> <li> <p>4 mg/day b.i.d</p> </li> <li> <p>6 mg/day b.i.d</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0002" title="AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ForetteF , AnandR , GharabawiG . A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). European Journal of Neurology1999;6:423‐9. ">B104</a> </p> <p>(Phase II)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.2 (7.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5 (3.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Belgium, France, UK, Norway, Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0007"> <li> <p>6 to 12 mg/day b.i.d.</p> </li> <li> <p>6 to 12 mg/day t.i.d</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] ">B303/B305</a>* </p> <p>(Phase III)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.0 (8.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0 (4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>France, Germany, Austria, Switzerland, Canada, USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0008"> <li> <p>1 to 4 mg b.i.d</p> </li> <li> <p>6 to 12 mg/day b.i.d., placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0004" title="FeldmanHH , LaneR . Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry2007;78(10):1056‐63. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B304</a>* </p> <p>(Phase III)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.4 (8.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5 (4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK, Ireland, Australia, Canada, RSA, Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0009"> <li> <p>2 to 12 mg/day b.i.d.</p> </li> <li> <p>2 to 12 mg/day t.i.d.</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a>* </p> <p>(Phase III)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.1 (8.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0 (4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0010"> <li> <p>3 mg/day t.i.d</p> </li> <li> <p>6 mg/day t.i.d</p> </li> <li> <p>9 mg/day b.i.d</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a>* </p> <p>(Phase III)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.5 (7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7 (4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0011"> <li> <p>1 to 4 mg per day b.i.d</p> </li> <li> <p>6 to 12 mg/day b.i.d.</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.8 (7.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0012"> <li> <p>6 to 12 mg/day b.i.d</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0013"> <li> <p>6 to 12 mg/day b.i.d.</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0014"> <li> <p>6 to 12 mg/day b.i.d.</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.1 (4.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0015"> <li> <p>6 to 12 mg/day b.i.d.</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Taiwan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0016"> <li> <p>3 to 6 mg/day b.i.d.</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Oral and patches</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>* </p> <p>(Phase III)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.3 (7.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.5 (3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>North, Central and South America, Asia, Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0017"> <li> <p>patch 9.5 mg/day</p> </li> <li> <p>patch 17.4 mg/day</p> </li> <li> <p>capsules 6 to 12 mg/day b.i.d.</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Patches</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>859</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.6 (7.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.6 (3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>multicentre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0018"> <li> <p>patch 4.6 mg/day</p> </li> <li> <p>patch 9.5 mg/day</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* These studies met the inclusion criteria of the main analysis comparing rivastigmine at the therapeutic doses versus placebo. </p> <p>b.i.d = bis in die in Latin, this means that a medication is taken two times a day, dividing the total daily dose into two doses. </p> <p>t.i.d = ter in die in Latin, this means that a medication is taken three times a day, dividing the total daily dose into three doses. </p> <p>MMSE = Mini‐Mental Health State Examination. The score range from 0 ( severe impairment) to 30 (normal). </p> </div> </div> <div class="table" id="CD001191-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Objectives of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Objective</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0001" title="AgidY , Dubois B on behalf of the International Rivastigmine Investigators, AnandR , GharabawiG . Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutic Research1998;59(12):837‐45. AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. "><b>B103</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To assess the short term (3 months) symptomatic efficacy and tolerability of rivastigmine 4 and 6 mg/day compared with placebo in patients with AD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001191-bbs2-0002" title="AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ForetteF , AnandR , GharabawiG . A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). European Journal of Neurology1999;6:423‐9. "><b>B104</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary: to determine the maximum tolerated dose (MTD) of rivastigmine in patients with mild to moderate dementia of the Alzheimer type (DAT) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Secondary: to determine ‐ a) whether tolerability is different when the drug is administered twice daily (b.i.d.) or three times daily (t.i.d.) ‐ b) if nausea and vomiting, associated with cholinesterase inhibition, can be controlled with antiemetics thereby increasing the MTD, and ‐ c) to assess the efficacy of rivastigmine at its MTD in comparison with that of placebo in the treatment of DAT </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] "><b>B303/B305</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary 1: to evaluate the efficacy of two non‐overlapping dose ranges of rivastigmine (1 to 4mg daily and 6 to 12 mg daily) versus placebo over a 26 week treatment period as assessed by two primary measures of outcome; change from baseline in ADAS‐Cog score and the CIBIC‐Plus score at week 26 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary 2: to evaluate the safety of the study medication as assessed by incidence of adverse events, clinical laboratory evaluations , vital signs, ECG recordings, and the results of physical examination made at baseline and throughout the study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Secondary: to assess dose‐efficacy and dose‐safety relationships for rivastigmine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001191-bbs2-0004" title="FeldmanHH , LaneR . Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry2007;78(10):1056‐63. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. "><b>B304</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary: to evaluate the efficacy and safety of individual highest well‐tolerated doses (range 6 to 12 mg daily) of rivastigmine given b.i.d. or t.i.d. for 26 weeks compared with placebo in the therapy of patients with probable Alzheimer's disease </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Secondary: to compare the twice daily and three times daily dosing regimens with respect to efficacy and safety to evaluate changes in activities of daily living (ADL) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. "><b>B351</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary: to evaluate the efficacy and safety of three fixed doses of rivastigmine (3, 6 and 9 mg/day) and placebo for 26 weeks of treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Secondary: to assess the dose‐efficacy and dose‐safety relationships for rivastigmine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary: to explore the pharmacokinetics of rivastigmine at doses of 3, 6 and 9 mg daily </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] "><b>B352</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary: to evaluate the efficacy and safety of two non‐overlapping dose ranges of rivastigmine (1 to 4 mg daily and 6 to 12 mg daily) and placebo for 26 weeks of treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Secondary: to assess the dose‐efficacy and dose‐safety relationships of rivastigmine. To investigate the relationship between plasma concentrations of rivastigmine and efficacy and safety </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary: to explore the pharmacokinetics of rivastigmine at doses of 1 to 4 and 6 to 12 mg daily </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. "><b>IDEAL</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To compare the efficacy,safety and tolerability of a novel rivastigmine transdermal patch with conventional rivastigmine capsules and placebo in patients with AD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. "><b>Karaman 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To evaluate the efficacy of rivastigmine for a period of 12 months in patients with advanced moderate AD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. "><b>Lopez‐Pousa 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To evaluate the safety and efficacy of rivastigmine in patients with more advanced AD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. "><b>Mowla 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To assess the effect of serotonin augmentation on cognition and ADL of patients with AD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. "><b>Ballard 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To determine whether rivastigmine was better than placebo for agitation and cognition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] "><b>Tai 2000</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To evaluate the safety and efficacy of Exelon compared with placebo in patients with probable Alzheimer's disease who had dementia ranging from mild to moderate degree </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. "><b>Nakamura 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To evaluate the efficacy, safety, and tolerability of the 5 cm<sup>2</sup> (9 mg loading dose, 4.6 mg/24 h delivery rate) and 10 cm<sup>2</sup> (18 mg loading dose, 9.5 mg/day delivery rate) rivastigmine patch in Japanese patients with AD </p> </td> </tr> </tbody> </table> </div> <p>Only randomised, double‐blinded placebo controlled trials or studies comparing different formulations were included in this review. Thirteen studies met the inclusion criteria of the review. </p> <p>Six trials, phase II and III, were all supported by Novartis Pharmaceuticals Corporation and were completed by 1996. They are identified by their Novartis or ADENA code (ADENA was the name given by Novartis to the Exelon Phase III clinical trials programme). The two phase II trials were designed to assess the tolerability, efficacy and safety of rivastigmine over three to four months. The four phase III trials were designed to assess the efficacy and safety of rivastigmine in patients with mild to moderately severe AD over six months. The trials had many features in common. They were all multicentre, randomised, double‐blind, parallel‐group trials. All trials compared rivastigmine with placebo, with at least two treatment groups of different rivastigmine regimens. </p> <p>Of the seven later trials, three were also sponsored by Novartis (<a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>; <a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a>; <a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a>). The key information about these seven trials is summarised as follows. </p> <p> <ul id="CD001191-list-0019"> <li> <p>There is limited information available about <a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a>, which has been published only as an abstract. This trial appeared to be an independent trial carried out in Taiwan. Eighty participants with mild to moderate AD were treated with rivastigmine or placebo for 26 weeks. No data were available to include in the meta‐analyses. </p> </li> <li> <p><a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a> was a small 26 week trial (n = 93) with three treatment arms, rivastigmine, quetiapine and placebo, of equal size. The objective was to compare the efficacy of rivastigmine and quetiapine for agitation in people with possible or probable AD who were living in institutions. We did not include any data from this trial in the meta‐analyses because of concerns about a high risk of attrition bias and exclusion of the most severely impaired patients from the analyses. </p> </li> </ul> </p> <p><a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a> and <a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a> aimed to investigate the efficacy of rivastigmine for patients with more advanced disease than those previously tested. </p> <p> <ul id="CD001191-list-0020"> <li> <p><a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a> was a small 12 month trial (n = 44, mean baseline MMSE = 12.2). We did not include data from this trial in our meta‐analyses due to concern about a high risk of bias. </p> </li> <li> <p><a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a> was a 6 month trial (n = 218, mean baseline MMSE = 8.8). In addition to the outcomes of cognitive function, activities of daily living and global clinical change, <a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a> was the earliest included trial to assess behavioural symptoms. </p> </li> <li> <p><a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a> was a 12 week trial in mild to moderate AD with three treatment groups, rivastigmine, rivastigmine plus fluoxetine and placebo. The rivastigmine plus fluoxetine group was not included in this review. There were 82 participants in total in the rivastigmine and placebo groups. We were not able to include any data from this trial in the meta‐analyses due to incomplete reporting of results. </p> </li> </ul> </p> <p><a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a> and <a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a> were the only trials to include transdermal rivastigmine. </p> <p> <ul id="CD001191-list-0021"> <li> <p><a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a> was a 6 month study (n = 1195) in mild to moderate AD, with 4 treatments arms, rivastigmine capsules, 2 doses of transdermal rivastigmine and placebo. </p> </li> <li> <p><a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a> was a 24 week dose finding trial in mild to moderate AD (n = 859) with 3 treatment arms, 2 doses of transdermal rivastigmine and placebo.. </p> </li> </ul> </p> <p>All studies used current diagnostic criteria for dementia (DSM‐IV) and probable AD (NINCDS‐ADRDA) (<a href="./references#CD001191-bbs2-0085" title="McKhannG , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology1984;34:939‐44. ">McKhann 1984</a>) except <a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a>, which did not give its diagnostic criteria. The severity of disease was mostly assessed by the MMSE rating scale, and patients that were included had MMSE scores of 10 to 26 inclusive apart from 2 studies (<a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a>; <a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a>), which randomised patients with MMSE scores of 3 to 12. The list of exclusions was not extensive. Patients with severe and unstable illnesses (cardiovascular or pulmonary disease, unstable diabetes mellitus, peptic ulceration within the preceding five years, evidence of alcohol or substance abuse) were excluded, as were individuals taking medications such as anticholinergic drugs, acetylcholine precursor health food supplements, memory enhancers, insulin and psychotropic drugs. The procedures followed were in accordance with the ethical standards of the relevant institutional committees on human experimentation and with the Declaration of Helsinki (<a href="./references#CD001191-bbs2-0079" title="Declaration of Helsinki. http://www.faseb.org/arvo/helsinki.htm. ">Helsinki declaration</a>). </p> </section> <section id="CD001191-sec-0050"> <h5 class="title">Interventions</h5> <p>Information about treatment groups and actual doses achieved are tabulated in <a href="#CD001191-tbl-0002">Table 1</a> and <a href="#CD001191-tbl-0004">Table 3</a> respectively. </p> <div class="table" id="CD001191-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Mean daily dose (mg/day) of rivastigmine achieved in the studies at different time points</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>treatment group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0001" title="AgidY , Dubois B on behalf of the International Rivastigmine Investigators, AnandR , GharabawiG . Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutic Research1998;59(12):837‐45. AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. "><b>B103</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0002" title="AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ForetteF , AnandR , GharabawiG . A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). European Journal of Neurology1999;6:423‐9. "><b>B104</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] "><b>B303/B305</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0004" title="FeldmanHH , LaneR . Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry2007;78(10):1056‐63. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. "><b>B304</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. "><b>B351</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] "><b>B352</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. "><b>IDEAL</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. "><b>Karaman 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. "><b>Lopez‐Pousa 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. "><b>Nakamura 2011</b> </a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 to 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>low b.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>medium b.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high b.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high t.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>low b.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>medium b.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high b.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high t.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>low patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>medium patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>medium patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high b.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>Exact doses not available for <a href="./references#CD001191-bbs2-0001" title="AgidY , Dubois B on behalf of the International Rivastigmine Investigators, AnandR , GharabawiG . Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutic Research1998;59(12):837‐45. AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ">B103</a>, <a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a>, <a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a>, <a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a>. </p> </div> </div> <p>Twelve studies investigated the oral form of rivastigmine, and one of these studies also included an arm randomised to a rivastigmine patch (<a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>). </p> <p>Earlier industry sponsored trials investigated a range of doses, from 2 mg/day to 12 mg/day in two or three divided doses. In later trials (<a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a>; <a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a>; <a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a>; <a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a>; <a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>) only the dose range of 6 to 12 mg/day was used to compare against placebo. <a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a> investigated doses of 3 to 6 mg/day in two divided doses. All studies with high oral doses achieved a mean daily dose of between 9.3 to 10.7 mg/day, except for <a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a> (8.3 mg/day) and <a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a> (8.5 mg/day). The mean daily doses achieved for medium doses were between 5.7 and 6 mg/day. Further information on the doses achieved was not available for four trials (<a href="./references#CD001191-bbs2-0001" title="AgidY , Dubois B on behalf of the International Rivastigmine Investigators, AnandR , GharabawiG . Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutic Research1998;59(12):837‐45. AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ">B103</a>; <a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a>; <a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a>; <a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a>). </p> <p>Two studies evaluated the safety and efficacy of patches. <a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a> investigated 6 to 12 mg/day capsules in 2 doses and the other 2 arms tested rivastigmine patches, a 10 cm<sup>2</sup> patch which delivered 9.5 mg/day and a 20 cm<sup>2</sup> patch which delivered 17.4 mg/day. Patients were titrated to their target dose in four week steps. Patients in the patch groups started with a 5 cm<sup>2</sup> patch until the target dose was achieved; in the capsule group they began with 3 mg/day, increased by steps of 3 mg/day. All patients had a rivastigmine or placebo patch once a day and a rivastigmine or placebo capsule twice a day. <a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a> investigateda 10 cm<sup>2</sup> patch which delivered 9.5 mg/day, a 5 cm<sup>2</sup> patch which delivered 4.6 mg/day and a placebo arm. Patients were titrated to their target patch dose over four week intervals, followed by an eight week maintenance period. </p> </section> <section id="CD001191-sec-0051"> <h5 class="title">Outcomes</h5> <p>The trials examined cognitive, functional and global effects, behavioural symptoms, as well as the safety and tolerability of rivastigmine. </p> <p>Apart from the outcome measures related to safety or adverse effects, all the outcomes for the effectiveness of rivastigmine were measured by questionnaires or psychometric tests. Different types of instruments were utilised to measure each outcome. The details of the outcomes measured and reported in each trial are summarised in <a href="#CD001191-tbl-0005">Table 4</a>. </p> <div class="table" id="CD001191-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Measured outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Cognitive function</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Activities of daily lIving</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Behavioural symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Physician rated global impression of change</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Other domains</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADAS‐Cog</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MMSE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Others</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PDS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Others</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CIBIC‐Plus</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Others</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0001" title="AgidY , Dubois B on behalf of the International Rivastigmine Investigators, AnandR , GharabawiG . Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutic Research1998;59(12):837‐45. AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ">B103</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OE, TMT, NOSGER, DSST, VRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0002" title="AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ForetteF , AnandR , GharabawiG . A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). European Journal of Neurology1999;6:423‐9. ">B104</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wechsler psychometric tests, NOSGER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] ">B303/B305</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAS‐CogA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0004" title="FeldmanHH , LaneR . Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry2007;78(10):1056‐63. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B304</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAS‐CogA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAS‐CogA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAS‐CogA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACDS‐ADL, DAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLOCK DRAWING, TMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACDS‐ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADCS‐CGIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB, BLESSED DEMENTIA SCALE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACDS‐ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI‐10, NPI‐4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> <p>ADCS‐CGIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WMS‐III,</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hamilton score</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MENFIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BEHAVE‐AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>x indicated that the study measured this outcome.</p> <p>The full names of these scales and their properties are described in <a href="#CD001191-sec-0028">Types of outcome measures</a>. </p> </div> </div> </section> <section id="CD001191-sec-0052"> <h5 class="title">1. Cognitive function</h5> <p> <ul id="CD001191-list-0022"> <li> <p>Alzheimer's Disease Assessment Scale (ADAS‐Cog) (<a href="./references#CD001191-bbs2-0093" title="RosenWG , MohsRC , DavisKL . A new rating scale for Alzheimer’s disease. American Journal of Psychiatry1984;41:356‐64. ">Rosen 1984</a>). ADAS‐Cog comprises 11 individual tests: spoken language ability (0 to 5), comprehension of spoken language (0 to 5), recall of test instructions (0 to 5), word finding difficulty (0 to 5), following commands (0 to 5), naming object (0 to 5), construction drawing (0 to 5), ideational praxis (0 to 5), orientation (0 to 8), word recall (0 to 10) and word recognition (0 to 12). The total score ranges from 0 to 70, the higher the score indicating greater impairment. </p> </li> <li> <p>The ADAS‐CogA total score is the ADAS‐Cog plus the attention item from the ADAS‐Noncog.</p> </li> <li> <p>The Mini‐Mental State Examination (MMSE) (<a href="./references#CD001191-bbs2-0071" title="FolsteinMF , FolsteinSE , McHughPR . ‘Mini‐Mental State’: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research1975;12:189‐98. ">Folstein 1975</a>) evaluates cognition in five areas: orientation, immediate recall, attention and calculation, delayed recall and language. The test takes only 15 minutes to administer and the scores range from 0 (severe impairment) to 30 (normal). </p> </li> <li> <p>The Severe Impairment Battery (SIB) (<a href="./references#CD001191-bbs2-0087" title="PanissetM , RoudierM , SaxtonJ , BollerF . Severe impairment battery: a neurological test for severely demented patients. Archives of Neurology1994;51:41‐5. ">Panisset 1994</a>; <a href="./references#CD001191-bbs2-0094" title="SaxtonJ , McGonigle‐GibsonK , SwihartA , MillerM , BollerF . Assessment of severely impaired patients: description and validation of a new neuropsychological test battery. Psychological Assessment1990;2:298‐303. ">Saxton 1990</a>) is a 40‐item questionnaire designed to assess the severity of cognitive dysfunction in advanced AD and is divided into 9 domains: memory, language, orientation, attention, praxis, vasospastically, construction, orientation to name and social interaction. The score ranges from 0 (greatest impairment) to 100 (no impairment). </p> </li> <li> <p>The Revised Wechsler Memory Scale (WMS‐R) (<a href="./references#CD001191-bbs2-0101" title="WechslerD . Wechsler Memory Scale‐Revised (WMS‐R). San Antonio: Psychological Corporation Harcourt Brace Jovanovich Inc, 1987. ">Wechsler 1987</a>) comprises a series of brief subtests, some taken from the WMS and each measuring a different facet of memory, which are summarised into five composite scores and finally two major scores using weights prescribed by Wechsler. Some of the tests were used in <a href="./references#CD001191-bbs2-0001" title="AgidY , Dubois B on behalf of the International Rivastigmine Investigators, AnandR , GharabawiG . Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutic Research1998;59(12):837‐45. AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ">B103</a>. </p> </li> <li> <p>The Fuld Object‐Memory Test (OME) (<a href="./references#CD001191-bbs2-0072" title="FuldPA . The Fuld object memory evaluation. Chicago: Steeling Instrument Co., 1981. ">Fuld 1981</a>) evaluates short term memory and learning by measuring the recall of 10 previously viewed objects. </p> </li> <li> <p>The Benton Visual Retention Test (VRT) (<a href="./references#CD001191-bbs2-0057" title="BentonAL . Revised visual retention test. 4th Edition. San Antonio, Texas: The Psychological Association, 1974. ">Benton 1974</a>) evaluates visual memory by assessing the accuracy of reproduction of each of 10 designs shown briefly to the individual. </p> </li> <li> <p>The Trail Making Test (TMT) (<a href="./references#CD001191-bbs2-0092" title="ReitanRM . The validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills1958;8:271‐6. ">Reitan 1958</a>) assesses the time taken to connect a series of 25 numbered dots. </p> </li> <li> <p>The Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change (ADCS‐CGIC) (<a href="./references#CD001191-bbs2-0095" title="SchneiderLS , OlinJT , DoodyRS , et al. Validity and reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders1997;11 Suppl 2:S22‐S32. ">Schneider 1997</a>) provides a single global rating of change from baseline, rated by an independent observer who has no access to the other efficacy or safety data. </p> </li> <li> <p>The Ten‐Point Clock Drawing Test (<a href="./references#CD001191-bbs2-0100" title="WatsonYI , ArfkenCL , BirgeSJ . Clock completion: an objective screening test for dementia. Journal of the American Geriatric Society1993;41:1235‐40. ">Watson 1993</a>) assesses visuospatial and executive functions. </p> </li> <li> <p>The Mental Function Impairment (MENFIS) (<a href="./references#CD001191-bbs2-0081" title="HommaA , NiinaR , IshiiT , HasegawaK . Development of a new rating scale for dementia in the elderly: Mental Function Impairment Scale (MENFIS). Japanese Journal of Geriatric Psychiatry1991;2:1217‐22. ">Homma 1991</a>) evaluates core symptoms of dementia including cognitive, motivational and emotional aspects based on an interview with the patient and carer. The score ranges from 0 to 78 (greater functional deficit). </p> </li> <li> <p>Digital substitution test (DSST).</p> </li> </ul> </p> </section> <section id="CD001191-sec-0053"> <h5 class="title">2. Activities of daily living</h5> <p> <ul id="CD001191-list-0023"> <li> <p>The Progressive Deterioration Scale (PDS) (<a href="./references#CD001191-bbs2-0066" title="DeJongR , OsterlundOW , RoyGW . Measurement of Quality‐of‐Life changes in patients with Alzheimer's Disease. Clinical Therapeutics1989;11(4):545‐54. ">DeJong 1989</a>) is an instrument with 29 items assessing the activities of daily living as rated by a carer. Each item is scored on a visual analogue scale of 0 to 100, and the total score is the mean item score. The score of 0 to 100 decreases with severity of dementia. </p> </li> <li> <p>The Alzheimer's Disease Cooperative Study activities of daily living inventory for severe Alzheimer's disease (ADCS‐ADL) (<a href="./references#CD001191-bbs2-0073" title="GalaskoD , SchmittFA , SanoM , et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders1997;11:33‐9. ">Galasko 1997</a>). This is a 19‐item scale for basic and complex abilities validated in patients with moderate to severe dementia. The total score ranges from 0 to 54 (no impairment). Items include basic activities of daily living (eating, bathing) and complex activities (operating taps, switching lights). </p> </li> <li> <p>The Caregiver Activity Survey (CAS) is completed by the caregiver and includes six items for which the caregiver estimates the amount of time spent in the previous 24 hours helping the patient with activities of daily living. </p> </li> <li> <p>The Nurses' Observation Scale for Geriatric Patients (NOSGER) (<a href="./references#CD001191-bbs2-0061" title="BrunnerC , SpiegelR . Eine Validierungsstudie mit der NOSGER (Nurses' Observation Scale for Geriatric Patients), einem neuen Beurteilungsinstrument für die Psychogeriatrie [Eine Validierungsstudie mit der NOSGER (Nurses' Observation Scale for Geriatric Patients), einem neuen Beurteilungsinstrument für die Psychogeriatrie]. Zeitschr für Psychologie1990;XIX(3):211‐9. ">Brunner 1990</a>) is designed to assess various cognitive functions and behaviour as related to activities of daily living and as assessed by a caregiver who sees the patient frequently. The NOSGER contains 6 x 5 = 30 items which were selected to assess the following dimensions: (a) memory, (b) self‐care, (c) instrumental activities of daily life, (d) mood, (e) disturbing behaviour, (f) social behaviour.The Disability Assessment for Dementia (DAD) is a 46‐item structured interview for the carer, scored 0 to 100 (least impairment), to evaluate activities of daily living (<a href="./references#CD001191-bbs2-0074" title="GelinasI , GauthierL , McIntyreM , GauthierS . Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. American Journal of Occupational Therapy1999;53:471‐81. ">Gelinas 1999</a>). </p> </li> </ul> </p> </section> <section id="CD001191-sec-0054"> <h5 class="title">3. Behavioural symptoms</h5> <p> <ul id="CD001191-list-0024"> <li> <p>The Neuropsychiatric Instrument (NPI) (<a href="./references#CD001191-bbs2-0065" title="CummingsJL , MegaM , GrayK , Rosenburg‐ThompsonS , CarusiDA , GornbeinJ . The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology1994;44:2308‐13. ">Cummings 1994</a>) is a 12‐item, carer rated instrument to evaluate behavioural and neuropsychiatric symptoms, including delusions, hallucinations, agitation and aggression, depression or dysphoria, anxiety, elation or euphoria, apathy, disinhibition, irritability, aberrant motor behaviour, night‐time behaviour and appetite or eating disorder. The frequency is rated from 1 (occasional, less than once a week) to 4 (very frequent) and severity from 1 (mild) to 3 (severe). The product of frequency and severity ranges from 1 to 12, with a total score ranging from 12 to 120 for the 10 domains summed. A lower score indicates improvement. </p> </li> <li> <p>The Cohen‐Mansfield Agitation Inventory (CMAI) (<a href="./references#CD001191-bbs2-0064" title="Cohen‐MansfieldJ . Assessment of disruptive behaviour/agitation in the elderly: function, methods and difficulties. Journal of Geriatric Psychiatry Neurology1995;8:52‐60. ">Cohen‐Mansfield 1995</a>) scale, range from 29 to 203, is widely used in nursing homes to assess agitation. The scale examines 29 types of agitated behaviour, including pacing, verbal or physical aggression, performing repetitious mannerisms, screaming, and general restlessness. The frequency of these behaviours is measured on a 7‐point scale, ranging from 1 (never occurs) to 7 (occurs several times an hour, and includes cluster scores for physical and verbal aggression, and total aggression. </p> </li> <li> <p>The Behavioural Pathology in AD (BEHAVE‐AD) assesses potentially remediable behavioural problems (agitation, aggression, affect, psychosis) in patients with AD. It consists of 22 symptoms grouped into 7 categories, each scored by a carer on a 4‐point scale (<a href="./references#CD001191-bbs2-0090" title="ReisbergB , FranssenE . Stage specific incidence of potentially remediable behavioral symptoms in aging and AD: a study of 120 patients using the BEHAVE‐AD. Bulletin of Clinical Neuroscience1989;54:95‐112. ">Reisberg 1989</a>). </p> </li> </ul> </p> </section> <section id="CD001191-sec-0055"> <h5 class="title">4. Physician rated global impression tests</h5> <p> <ul id="CD001191-list-0025"> <li> <p>A Clinician's Interview‐Based Impression of Change scale (CIBIC‐Plus) (<a href="./references#CD001191-bbs2-0091" title="ReisbergB , FerrisSH . CIBIC‐plus interview guide. Unknown, 1994. ">Reisberg 1994</a>) includes information supplied by the caregiver and patient. It provides a global rating of patient function in four areas: general, cognitive, behaviour and activities of daily living. All patients are scored as 4 at baseline; subsequent assessment on a scale of 1 to 7 is relative to baseline, with 1 showing marked improvement and 7 marked worsening. </p> </li> <li> <p>The Global Deterioration Scale (GDS) (<a href="./references#CD001191-bbs2-0089" title="ReisbergB , FerrisSH , DeLeonMJ , CrookT . The global deterioration scale for assessment of primary degenerative dementia. American Journal of Psychiatry1982;139:1136‐9. ">Reisberg 1982</a>) is reported as a score from 1 to 7, 1 indicating normality to 7 indicating very severe dementia, and is a global assessment carried out by a clinician who has access to all information about a patient. </p> </li> <li> <p>The Clinical Global Impression of Change (CGIC) (<a href="./references#CD001191-bbs2-0076" title="GuyW (editor) . ECDEU Assessment manual for psychopharmacology. Rockville: National Institute of Mental Health, 1976. ">Guy 1976</a>) is a global rating of all domains of a patient's current condition in comparison with baseline. It is a 7‐point scale ranging from 1 (very much improved) to 7 (very much worse), with 4 indicating no change. The assessment is conducted by the same clinician at both time points with input from relatives or carers. </p> </li> </ul> </p> </section> <section id="CD001191-sec-0056"> <h5 class="title">5. Acceptability of treatment, as measured by withdrawal from trial</h5> <p>In anticipation of the typical gastrointestinal adverse events associated with cholinesterase inhibitors, which can be dose‐dependent, the various arms of the older trials compared both different doses and twice or thrice daily dosage schedules. Three fixed doses were tested in <a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a>, but the other trials aimed for a maximum tolerated dose within a prescribed range. The period of titration was longer for larger doses and varied between 3 and 12 weeks. The later trials tested a transdermal patch formulation which provided continuous delivery of the drug with the objective of improving tolerability. The mean daily doses of rivastigmine at different time points are presented in <a href="#CD001191-tbl-0004">Table 3</a>. Safety and tolerability were evaluated by recording adverse events and serious adverse events. In addition, routine physical examinations with blood and urine analyses were performed and vital signs and electrocardiograms were checked at all clinic visits. Seven trials reported the withdrawal rate at 26 weeks (<a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] ">B303/B305</a>; <a href="./references#CD001191-bbs2-0004" title="FeldmanHH , LaneR . Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry2007;78(10):1056‐63. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B304</a>; <a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a>; <a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a>; <a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>; <a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a>; <a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a>). </p> </section> <section id="CD001191-sec-0057"> <h5 class="title">6. Incidence of adverse events</h5> <p>The studies reported the types of adverse events reported by patients, and the number of patients experiencing these events, usually focusing on the most commonly experienced adverse events. A wide range of adverse events which were consistent with the anticholinergic properties of rivastigmine were reported, including gastrointestinal adverse events such as nausea, vomiting, abdominal pain or discomfort, and diarrhoea. Other adverse events reported included falls, insomnia, agitation, weight loss, headache, dizziness, and cutaneous adverse events where patches were used. </p> <p>The same seven studies which reported on withdrawal from the trial before completion of the study also reported the number of patients who experienced at least one adverse event. Most of these studies had defined a safety population which is the basis for the adverse events analyses. </p> </section> <section id="CD001191-sec-0058"> <h5 class="title">7. Quality of life of patients and carers</h5> <p>Only one study reported changes in the NPI‐D carer distress scale. This study reported the change from baseline at 24 weeks (<a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>). </p> </section> </section> <section id="CD001191-sec-0059"> <h4 class="title">Excluded studies</h4> <p>Please see <a href="./references#CD001191-sec-0143" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD001191-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>(<a href="#CD001191-fig-0001">Figure 1</a> and <a href="#CD001191-fig-0002">Figure 2</a>) </p> <div class="figure" id="CD001191-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001191-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD001191-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001191-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001191-sec-0061"> <h4 class="title">Allocation</h4> <p>All the trials sponsored by Novartis were considered to be at low risk of bias for randomisation and allocation concealment, other than <a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a> where it was difficult to be sure whether allocation was concealed effectively. </p> <p>Of the independent trials, <a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a> had a low risk of allocation bias, with clearly described procedures. However, the risk of bias in this domain was unclear for <a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a> (an abstract), <a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a> and <a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a> because there were no descriptions of methods. <a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a> was of particular concern as only "participants who tolerated the drug well and perceived benefit were invited to continue rivastigmine treatment" after eight weeks. </p> </section> <section id="CD001191-sec-0062"> <h4 class="title">Blinding</h4> <p>All trials were double‐blinded and placebo controlled, with precautions taken to maintain the blinding such as ensuring the placebo was identical in appearance to the active treatment. However, in <a href="./references#CD001191-bbs2-0002" title="AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ForetteF , AnandR , GharabawiG . A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). European Journal of Neurology1999;6:423‐9. ">B104</a> the placebo group received the treatment twice daily whereas one of the treatment arms received the intervention three times daily. There were no descriptions of additional steps taken to mask this. The difference in the number of times the capsules were taken could have unmasked the three times per day group. The effectiveness of double‐blinding in <a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a> was also unclear because all patients in this study had received the placebo during the six week pre‐randomisation run‐in period. </p> <p>Of the two studies testing patches, <a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a> was considered to be at low risk of bias for blinding as a double dummy was used. <a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a> stated that "patients, investigator staff, persons performing the assessments and data analysts are all blinded", but it was unclear how this was achieved since the study had used different patch sizes (2.5, 5, 7.5 and 10 cm<sup>2</sup>) to achieve the target dose. </p> </section> <section id="CD001191-sec-0063"> <h4 class="title">Incomplete outcome data</h4> <p>Attrition bias was a major concern. There were substantial losses from <a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a> where 19% (6/31) of those randomised to rivastigmine did not start treatment compared with 6% of those randomised to placebo. Only 18/31 in the rivastigmine group completed the trial compared with 27/31 in the placebo group. Those with a low baseline score on the Severe Impairment Battery (SIB) were not included in the analyses. These concerns led us to exclude data from <a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a> from the meta‐analyses. </p> <p><a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a>, although the longest duration included trial (52 weeks), lost very few patients: only 3 of 24 in the rivastigmine group and none from the placebo group. This was a much lower rate of loss than for any other trial. </p> <p>For the other 11 studies missing assessments caused major problems in the analysis and interpretation of the results. Approximately 17% of patients from the 1 to 4 mg daily and placebo groups and 35% of patients from the 6 to 12 mg daily groups left the trial before completing treatment. If patients dropped out at random from each group, that is the dropout was not associated with the treatment, the comparisons between groups are not biased but estimates of differences are reduced in precision. However, the dropout rates were not random and were related to treatment. Various methods were used in the trials for dealing with missing data. </p> <p>The older trials (<a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] ">B303/B305</a>; <a href="./references#CD001191-bbs2-0004" title="FeldmanHH , LaneR . Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry2007;78(10):1056‐63. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B304</a>; <a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a>; <a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a>) reported in detail the methods using for dealing with missing data. Approximately a third of the patients who dropped out contributed endpoint data (retrieved drop out (RDO)). The ITT analyses included the completers (observed cases (OC)) data and the RDO data, and for the remainder of the patients the last available assessment (last observation carried forward (LOCF)). This remainder comprised approximately 6% of the patients in the placebo and 1 to 4 mg daily groups, and 24% for the 6 to 12 mg daily group at 26 weeks. An overestimate of the outcome effect would be expected. </p> <p>In order to compare the different methods of dealing with missing assessments, for two outcomes (ADAS‐Cog and CIBIC‐Plus) we conducted meta‐analyses on three different groups of patients: OC only, RDO + OC, and ITT (OC + RDO + LOCF). The results are presented in <a href="#CD001191-tbl-0006">Table 5</a>. These analyses showed that compared with OC or RDO + OC, the ITT analyses did not produce results favouring rivastigmine, indeed the opposite was true but the differences between results were small. Therefore, the ITT analyses were considered satisfactory and were reported for all other outcomes. Further analysis of the data from the ITT, the OC and RDO + OC analyses to investigate the size and direction of the bias due to differential dropouts from the arms of the rivastigmine trials (<a href="./references#CD001191-bbs2-0059" title="BirksJ . The evidence for the efficacy of cholinesterase inhibitors in the treatment of Alzheimer's disease is convincing. International Psychogeriatrics2008;20(2):279‐86. ">Birks 2008</a>) led to the conclusion that the absolute size of the bias was small and the direction could not be ascertained. </p> <div class="table" id="CD001191-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Comparison of different methods of dealing with missing values</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rivastigmine n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>placebo n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>probability level</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% confidence limits</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>1 to 4 mg daily versus placebo, ADAS‐Cog measured as change from baseline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.87, 0.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.08, 0.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐0.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.96, 0.23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.66, ‐0.48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.86, ‐0.52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.99, ‐0.67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐0.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.48, ‐0.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐0.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.72, ‐0.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.80, ‐0.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>6 to 12 mg daily versus placebo, ADAS‐Cog measured as change from baseline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.96, ‐1.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.33, ‐1.27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.89, ‐0.88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>6 to 12 mg daily versus placebo, ADAS‐Cog measured as change from baseline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.30,‐ 1.29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐2.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.96, ‐1.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐2.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.69, ‐1.55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐2.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.65, ‐1.54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐2.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.29, ‐1.94</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐2.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.03, ‐1.74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>1 to 4 mg daily versus placebo, CIBIC‐Plus measured as no change or worse</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72, 1.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72, 1.23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72, 1.22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75, 1.26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours placebo</p> <p>Peto OR 1.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80, 1.37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours placebo</p> <p>Peto OR 1.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78, 1.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55, 0.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50, 0.89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52, 0.91</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>1 to 4 mg daily versus placebo, CIBIC‐Plus measured as no change or worse</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60, 0.92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58, 0.91</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>952</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60, 0.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65, 1.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>741</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57, 0.91</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62, 0.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55, 0.85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49, 0.81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51, 0.82</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>The results for two outcomes, ADAS‐Cog and CBIC at 12, 18 and 26 weeks, have been pooled for 3 studies, <a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] ">B303/B305</a>, <a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a>. <a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a>. These studies reported results for 3 populations, intention‐to‐treat (ITT), completers (OC), and completers + retrieved dropout (RDO + OC). The table reports the results of the meta‐analyses for 2 comparisons (1 to 4 mg daily versus placebo and 6 to 12 mg/day versus placebo) for the 3 populations at the 3 time points. </p> </div> </div> </section> <section id="CD001191-sec-0064"> <h4 class="title">Selective reporting</h4> <p>For most of the studies the risk of reporting bias across all outcomes was difficult to judge. A few of the studies had listed the Caregiver Activities Survey (CAS) as an outcome in their protocols but these were not reported in the study results. In addition <a href="./references#CD001191-bbs2-0004" title="FeldmanHH , LaneR . Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry2007;78(10):1056‐63. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B304</a> and <a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a>, two large randomised trials, were not published. Our data were obtained from information provided by Novartis Ltd. </p> <p>For three of the studies (<a href="./references#CD001191-bbs2-0002" title="AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ForetteF , AnandR , GharabawiG . A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). European Journal of Neurology1999;6:423‐9. ">B104</a>; <a href="./references#CD001191-bbs2-0004" title="FeldmanHH , LaneR . Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry2007;78(10):1056‐63. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B304</a>; <a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a>) sufficient information was available from the study protocols and we considered these as low risk of bias. However, there was insufficient information to assess the risk of reporting bias in the other studies. </p> </section> <section id="CD001191-sec-0065"> <h4 class="title">Other potential sources of bias</h4> <p>Out of these 13 studies included in the review, only four (<a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a>; <a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a>; <a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a>; <a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a>) were conducted without direct sponsorship or funding from the manufacturer, Novartis Pharma, but none provided data that could be included in the review. </p> <p><a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a> reported standard deviations for the outcome measures that were an order of magnitude smaller than those seen in any other trial. We have asked the authors for clarification of these unusual findings but have not received a reply. </p> </section> </section> <section id="CD001191-sec-0066"> <h3 class="title" id="CD001191-sec-0066">Effects of interventions</h3> <p>See: <a href="./full#CD001191-tbl-0001"><b>Summary of findings for the main comparison</b> Rivastigmine compared to placebo for Alzheimer's disease</a> </p> <p>There are 13 included trials but 4 (<a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a>; <a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a>; <a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a>; <a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a>) did not contribute to the analyses. Data from <a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a> was excluded because of the high attrition rate from the rivastigmine group and concern over the elimination from the analyses of patients with a low baseline score. Data from <a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a> could not be included due to incomplete reporting. No data could be used from <a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a> as the trial report provided insufficient information. The data from <a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a> were of concern because of the potential for biased results and were omitted from the analyses. Although the longest duration trial, 52 weeks, only 3 of 24 in the rivastigmine group and none from the placebo group were lost. This was a much lower rate of loss than for any other trial. The numbers randomised were not reported but it was stated that patients were excluded at eight weeks if they did not appear to benefit. </p> <p>In order to meet the objectives of the review we conducted analyses comparing various doses and formulations of rivastigmine with placebo or comparing different formulations of rivastigmine. </p> <p>The rating scales and cognitive tests used differ in the direction representing improvement. A decrease in score indicates clinical improvement with the ADAS‐Cog, the CIBIC‐Plus and the GDS, while an increase shows improvement for the PDS and MMSE. </p> <section id="CD001191-sec-0067"> <h4 class="title">Comparison of rivastigmine (6 to 12 mg/day twice daily capsules or 10 cm<sup>2</sup> (9.5 mg/day) patch) with placebo </h4> <section id="CD001191-sec-0068"> <h5 class="title">Cognitive function</h5> <p>The meta‐analysis, using weighted mean differences (WMDs), revealed a benefit on cognitive function as measured by the ADAS‐Cog test scores for rivastigmine compared with placebo at 26 weeks (ITT analysis, WMD ‐1.79; 95% CI ‐2.21 to ‐1.37, P &lt; 0.00001, 6 studies). </p> <p>The MMSE showed similar results in favour of rivastigmine at 26 weeks compared with placebo (ITT analysis, WMD 0.74; 95% CI 0.52 to 0.97, P &lt; 0.00001, 6 studies). </p> </section> <section id="CD001191-sec-0069"> <h5 class="title">Activities of daily living</h5> <p>The meta‐analysis, using standardised mean differences (SMDs), showed an improvement associated with rivastigmine compared with placebo at 26 weeks (ITT analysis, WMD 0.20; 95% CI 0.13 to 0.27, P &lt; 0.00001, 6 studies). </p> </section> <section id="CD001191-sec-0070"> <h5 class="title">Global assessment</h5> <p>The seven‐point CIBIC‐Plus scale, or the ADCS‐CGIC scale, measuring global clinical state was dichotomized by counting those showing no change or decline against those showing improvement. There were benefits associated with rivastigmine compared with placebo at 26 weeks (ITT analysis, 1339/1848 rivastigmine, 1197/1490 placebo) (OR 0.68; 95%CI 0.58 to 0.80, P &lt; 0.00001, 7 studies). </p> </section> <section id="CD001191-sec-0071"> <h5 class="title">Behavioural symptoms</h5> <p>Three studies (<a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>; <a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a>; <a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a>) assessed behavioural symptoms using the Neuropsychiatric Instrument (NPI‐10 and NPI‐12). There was no difference between rivastigmine and placebo at 26 weeks. </p> </section> <section id="CD001191-sec-0072"> <h5 class="title">Withdrawals before the end of treatment</h5> <p>The meta‐analysis of withdrawals before the end of treatment showed a significant difference in favour of placebo compared with rivastigmine 26 weeks (571/2038 rivastigmine, 240/1531 placebo) (OR 2.06; 95%CI 1.74 to 2.45, P &lt; 0.00001, 7 studies). </p> </section> <section id="CD001191-sec-0073"> <h5 class="title">Adverse events</h5> <p>The meta‐analysis of numbers of patients with at least one adverse event showed that at 26 weeks there was a significant difference between the rivastigmine and placebo groups in favour of placebo (1637/2025 rivastigmine, 1123/1562 placebo) (OR 2.16; 95%CI 1.82 to 2.57, P &lt; 0.00001, 7 studies). </p> </section> <section id="CD001191-sec-0074"> <h5 class="title">Quality of life of carers</h5> <p>One study reported the changes in NPI‐D carer distress scale from baseline and this was reported at 24 weeks (<a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>). No significant difference was detected (MD 0.10; 95% CI ‐0.91 to 1.11, 1 study). </p> </section> </section> <section id="CD001191-sec-0075"> <h4 class="title">Comparison of rivastigmine (1 to 4 mg/day and 6 to 12 mg/day twice daily capsules) with placebo </h4> <section id="CD001191-sec-0076"> <h5 class="title">Cognitive function</h5> <p>The meta‐analysis, using WMDs, revealed a benefit on cognitive function as measured by ADAS‐Cog test scores for the lower dose rivastigmine compared with placebo at 26 weeks, but not at 12 weeks; and for the higher dose at 12 and 26 weeks: </p> <p> <ul id="CD001191-list-0026"> <li> <p>rivastigmine 1 to 4 mg/day at 12 weeks (ITT analysis, WMD ‐0.31; 95% CI ‐0.87 to 0.25, P = 0.01, 3 studies); </p> </li> <li> <p>rivastigmine 6 to 12 mg/day at 12 weeks (ITT analysis, WMD ‐1.49; 95% CI ‐1.96 to ‐1.01, P &lt; 0.00001, 4 studies); </p> </li> <li> <p>rivastigmine 1 to 4 mg/day at 26 weeks (ITT analysis, WMD ‐0.84; 95% CI ‐1.48 to ‐0.19, P = 0.01, 3 studies); </p> </li> <li> <p>rivastigmine 6 to 12 mg/day at 26 weeks (ITT analysis, WMD ‐1.99; 95% CI ‐2.49 to ‐1.50, P &lt; 0.00001, 5 studies). </p> </li> </ul> </p> <p>The MMSE showed similar results in favour of lower dose rivastigmine at 26 weeks and higher dose rivastigmine at 26 weeks, compared with placebo: </p> <p> <ul id="CD001191-list-0027"> <li> <p>rivastigmine 1 to 4 mg/day at 26 weeks (ITT analysis, WMD 0.43; 95% CI 0.08 to 0.78, P = 0.02, 3 studies); </p> </li> <li> <p>rivastigmine 6 to 12 mg/day at 26 weeks (ITT analysis, WMD 0.82; 95% CI 0.56 to 1.08, P &lt; 0.00001, 5 studies). </p> </li> </ul> </p> <p>One study (<a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a>) used the Severe Impairment Battery (SIB), which showed benefit associated with higher dose rivastigmine compared with placebo at 26 weeks (MD 4.53; 95% CI 0.47 to 8.59, P = 0.03). </p> </section> <section id="CD001191-sec-0077"> <h5 class="title">Activities of daily living</h5> <p>The PDS (carer assessment of the activities of daily living) showed an improvement associated with higher dose, but not lower dose, rivastigmine compared with placebo at 12 and 26 weeks: </p> <p> <ul id="CD001191-list-0028"> <li> <p>rivastigmine 1 to 4 mg/day at 12 weeks (WMD ‐0.77; 95% CI ‐1.84 to 0.30, 3 studies);</p> </li> <li> <p>rivastigmine 1 to 4 mg/day at 26 weeks (WMD ‐0.38; 95% CI ‐1.61 to 0.84) (3 studies);</p> </li> <li> <p>rivastigmine 6 to 12 mg/day at 12 weeks (WMD 1.08; 95% CI 0.19 to 1.98, P = 0.02, 4 studies); </p> </li> <li> <p>rivastigmine 6 to 12 mg/day at 26 weeks (WMD 2.15; 95% CI 1.13 to 3.16, P &lt; 0.0001, 4 studies). </p> </li> </ul> </p> <p>One study (<a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>) assessing activities of daily living (ADL) using the ADCS‐ADL scale showed benefit for 6 to 12 mg/day at 24 weeks (MD 1.80; 95% CI 0.20 to 3.40, P = 0.03). </p> </section> <section id="CD001191-sec-0078"> <h5 class="title">Global assessment</h5> <p>The seven‐point CIBIC‐Plus scale, or the ADCS‐CGIC scale, measuring global clinical state was dichotomized by counting those showing no change or decline against those showing improvement (as set out in the study protocols by Novartis) and analysed using the Peto OR. There were benefits associated with lower dose rivastigmine compared with placebo at 26 weeks, but not at 12 weeks; and benefits with the higher dose at both 12 and 26 weeks compared with placebo: </p> <p> <ul id="CD001191-list-0029"> <li> <p>rivastigmine 14 mg/day at 12 weeks (ITT analysis, 456/608 rivastigmine, 466/612 placebo) (OR 0.93; 95% CI 0.72 to 1.21, 3 studies); </p> </li> <li> <p>rivastigmine 6 to 12 mg/day at 12 weeks (ITT analysis, 688/950 rivastigmine, 645/825 placebo) (OR 0.74; 95% CI 0.60 to 0.92, P = 0.008, 4 studies); </p> </li> <li> <p>rivastigmine 1 to 4 mg/day at 26 weeks (ITT analysis, 457/614 rivastigmine, 500/623 placebo) (OR 0.71; 95% CI 0.55 to 0.93, P = 0.01, 3 studies); </p> </li> <li> <p>rivastigmine 6 to 12 mg/day at 26 weeks (ITT analysis, 957/1330 rivastigmine, 971/1223 placebo) (OR 0.66; 95% CI 0.55 to 0.79, P &lt; 0.00001, 6 studies). </p> </li> </ul> </p> <p>The GDS (global assessment) carried out at 26 weeks by a clinician who had access to all information about a patient was dichotomized by counting those showing moderately severe, severe or very severe dementia against those showing moderate or mild dementia. Using the Peto OR to compare with placebo, there were benefits associated with 6 to 12 mg daily rivastigmine (ITT analysis, 579/1056 on rivastigmine showed the worse condition compared to 511/868 on placebo) (OR 0.78; 95% CI 0.64 to 0.94, P = 0.01, 4 studies) but not with 1 to 4 mg daily rivastigmine. </p> </section> <section id="CD001191-sec-0079"> <h5 class="title">Behavioural symptoms</h5> <p>Two studies (<a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>; <a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a>) assessed behavioural symptoms using the NPI (NPI‐10 and NPI‐12). There was no difference between rivastigmine and placebo: </p> <p> <ul id="CD001191-list-0030"> <li> <p>rivastigmine 6 to 12 mg/day at 26 weeks (ITT analysis, WMD ‐0.06; 95% CI ‐0.20 to 0.09, 2 studies). </p> </li> </ul> </p> </section> <section id="CD001191-sec-0080"> <h5 class="title">Withdrawals before the end of treatment</h5> <p>The meta‐analyses of withdrawals before the end of treatment showed no significant differences between withdrawals from the 1 to 4 mg daily rivastigmine group and from the placebo group at 12 and 26 weeks. There were significant differences for the higher dose group in favour of placebo at 12 and 26 weeks: </p> <p> <ul id="CD001191-list-0031"> <li> <p>rivastigmine 1 to 4 mg/day at 12 weeks (17/136 rivastigmine, 8/133 placebo) (OR 2.15; 95% Cl 0.95 to 4.89, 1 study); </p> </li> <li> <p>rivastigmine 1 to 4 mg/day at 26 weeks (113/644 rivastigmine, 113/646 placebo) (OR 1.01; 95% CI 0.75 to 1.34, 3 studies); </p> </li> <li> <p>rivastigmine 6 to 12 mg/day at 12 weeks (20/133 rivastigmine, 8/133 placebo) (OR 2.60; 95% CI 1.19 to 5.68, P = 0.02, 1 study); </p> </li> <li> <p>rivastigmine 6 to 12 mg/day at 26 weeks (448/1458 rivastigmine, 1194/1243 placebo) (OR 2.19; 95% CI 1.83 to 2.63, P &lt; 0.00001, 6 studies). </p> </li> </ul> </p> </section> <section id="CD001191-sec-0081"> <h5 class="title">Adverse events</h5> <p>Most adverse events occurred within the titration period. The meta‐analyses of numbers of patients with at least one adverse event showed that by the end of the titration period and at 26 weeks there were no significant differences between the lower dose rivastigmine and placebo groups. There were, however, significant differences between the higher dose rivastigmine and placebo groups in favour of placebo by the end of the titration period and at 26 weeks: </p> <p> <ul id="CD001191-list-0032"> <li> <p>rivastigmine 1 to 4 mg/day at the end of the titration period (440/644 rivastigmine, 437/646 placebo) (OR 1.04; 95% Cl 0.82 to 1.31, 3 studies); </p> </li> <li> <p>rivastigmine 1 to 4 mg/day at 26 weeks (509/644 rivastigmine, 518/646 placebo) (OR 0.93; 95% CI 0.71 to 1.23, 3 studies); </p> </li> <li> <p>rivastigmine 6 to 12 mg/day at the end of the titration period (920/1072 rivastigmine, 584/878 placebo) (OR 2.96; 95% CI 2.39 to 3.68, P &lt; 0.00001, 4 studies); </p> </li> <li> <p>rivastigmine 6 to 12 mg/day at 26 weeks (1242/1450 rivastigmine, 901/1276 placebo) (OR 2.49; 95% CI 2.05 to 3.02, P &lt; 0.00001, 6 studies). </p> </li> </ul> </p> <p>A similar pattern was seen for the number of patients with at least one severe adverse event. The rivastigmine 1 to 4 mg daily group did not differ significantly from the placebo group, but there were significant differences between the rivastigmine 6 to 12 mg daily and placebo groups in favour of the latter for the titration period: </p> <p> <ul id="CD001191-list-0033"> <li> <p>rivastigmine 1 to 4 mg/day at the end of the titration period (48/644 rivastigmine, 51/646 placebo) (OR 0.94; 95% CI 0.62 to 1.42, 3 studies); </p> </li> <li> <p>rivastigmine 6 to 12 mg/day at the end of the titration period (130/1052 rivastigmine versus 61/868 placebo) (OR 1.88; 95% CI 1.39 to 2.55, P &lt; 0.0001, 4 studies). </p> </li> </ul> </p> <p>There were many types of adverse events reported and only the significant results are reported here. There were significant differences in favour of placebo for the rivastigmine 6 to 12 mg daily group by the end of the titration period and by 26 weeks for the number of patients suffering nausea, vomiting, diarrhoea, anorexia, headache, syncope, abdominal pain and dizziness. There were significant differences in favour of placebo for the rivastigmine 1 to 4 mg daily group compared to placebo by the end of the titration period and by 26 weeks for the number of patients suffering nausea, vomiting, diarrhoea and anorexia. </p> </section> <section id="CD001191-sec-0082"> <h5 class="title">Withdrawals before the end of treatment due to adverse events</h5> <p>The meta‐analyses of withdrawals at 26 weeks due to adverse events showed no significant differences in withdrawals from the lower dose rivastigmine and placebo groups. There were, however, significant differences between the rivastigmine 6 to 12 mg daily and placebo groups in favour of placebo (291/1453 versus 94/1276) (OR 2.73, 95% CI 2.19 to 3.41, P &lt; 0.00001, 6 studies). </p> </section> </section> <section id="CD001191-sec-0083"> <h4 class="title">Comparison of rivastigmine (20 cm<sup>2</sup> (17.4 mg/day) patch) with placebo </h4> <section id="CD001191-sec-0084"> <h5 class="title">Cognitive function</h5> <p>The meta‐analysis, using MDs, showed that rivastigmine had a benefit compared with placebo for cognitive function as measured by the ADAS‐Cog at 24 weeks: </p> <p> <ul id="CD001191-list-0034"> <li> <p>rivastigmine (ITT analysis, MD ‐2.60; 95% CI ‐3.72 to ‐1.48, P &lt; 0.00001, 1 study).</p> </li> </ul> </p> <p>The MMSE showed similar results in favour of rivastigmine at 26 weeks, compared with placebo: </p> <p> <ul id="CD001191-list-0035"> <li> <p>rivastigmine (ITT analysis, MD 0.90; 95% CI 0.32 to 1.48, P = 0.002, 1 study).</p> </li> </ul> </p> <p>The TMT‐A showed similar results in favour of rivastigmine at 26 weeks, compared with placebo: </p> <p> <ul id="CD001191-list-0036"> <li> <p>rivastigmine (ITT analysis, MD ‐14.20; 95% CI ‐24.11 to ‐4.29, P = 0.005, 1 study).</p> </li> </ul> </p> <p>There was no significant difference between rivastigmine and placebo for the clock drawing test. </p> </section> <section id="CD001191-sec-0085"> <h5 class="title">Activities of daily living</h5> <p>The ADCS‐ADL showed benefit in favour of rivastigmine compared with placebo at 24 weeks: </p> <p> <ul id="CD001191-list-0037"> <li> <p>rivastigmine (ITT analysis, MD 2.30; 95% CI 0.52 to 4.08, P = 0.01, 1 study).</p> </li> </ul> </p> </section> <section id="CD001191-sec-0086"> <h5 class="title">Behavioural symptoms</h5> <p>One study assessed behavioural symptoms using the NPI (NPI‐12). There was no difference between rivastigmine and placebo (ITT analysis, MD ‐0.60; 95% CI ‐2.88 to 1.68, 1 study). </p> </section> <section id="CD001191-sec-0087"> <h5 class="title">Withdrawals before the end of treatment</h5> <p>There was a significant difference between rivastigmine and placebo in favour of placebo for total withdrawals before the end of treatment (62/303 rivastigmine compared with 36/302 placebo) (OR 1.90; 95% CI 1.22 to 2.97, P = 0.005). </p> </section> <section id="CD001191-sec-0088"> <h5 class="title">Adverse events</h5> <p>There was a significant difference between rivastigmine and placebo in favour of placebo for the total number of patients that had at least one adverse event by 24 weeks (200/303 rivastigmine compared with 139/302 placebo) (OR 2.28; 95% CI 1.64 to 3.16, P &lt; 0.00001). </p> <p>There was a significant difference between rivastigmine and placebo in favour of placebo for the total number of patients that had at least one adverse event of dizziness (21/303 compared with 7/302) (ITT analysis, OR 3.14; 95% CI 1.31 to 7.50, P = 0.01), nausea (64/303 compared with 15/302) (OR 5.12; 95% CI 2.85 to 9.22, P &lt; 0.00001), vomiting (57/303 compared with 10/302) (ITT analysis, OR 6.77; 95% CI 3.38 to 13.53, P &lt; 0.00001), weight decrease (23/303 compared with 4/302) (ITT analysis, OR 6.12; 95% CI 2.09 to 17.92, P = 0.0009), and decreased appetite (15/303 compared with 3/302) (ITT analysis, OR 5.19; 95% CI 1.49 to 18.12, P = 0.01, 1 study). </p> </section> <section id="CD001191-sec-0089"> <h5 class="title">Withdrawals before the end of treatment due to adverse events</h5> <p>The meta‐analyses of withdrawals at 26 weeks due to adverse events showed no significant differences in withdrawals from the rivastigmine and placebo groups (26/303 rivastigmine compared with 15/302 placebo) (OR 1.80; 95% CI 0.93 to 3.46, 1 study). </p> </section> <section id="CD001191-sec-0090"> <h5 class="title">Quality of life of carers</h5> <p>One study assessed the NPI‐D carer distress scale at 24 weeks (<a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>). No significant difference between rivastigmine and placebo was detected (ITT analysis, MD 0.00; 95% CI ‐1.07 to 1.07). </p> </section> </section> <section id="CD001191-sec-0091"> <h4 class="title">Comparison of rivastigmine (10 cm<sup>2</sup> (9.5 mg/day) patch) with placebo </h4> <section id="CD001191-sec-0092"> <h5 class="title">Cognitive function</h5> <p>The meta‐analysis, using WMDs and MDs, showed a benefit of the 10 cm<sup>2</sup> rivastigmine patch on cognitive function as measured by the ADAS‐Cog, MMSE, TMT‐A and MENFIS at 24 weeks: </p> <p> <ul id="CD001191-list-0038"> <li> <p>ADAS‐cog (ITT analysis, WMD ‐1.34; 95% CI ‐2.02 to ‐0.66, P = 0.0001, 2 studies);</p> </li> <li> <p>MMSE (ITT analysis, WMD 0.64; 95% CI 0.26 to 1.02, P = 0.0009, 2 studies);</p> </li> <li> <p>TMT‐A (ITT analysis, MD ‐20.0; 95% CI ‐29.8 to ‐10.2, P &lt; 0.0001, 1 study);</p> </li> <li> <p>MENFIS (ITT analysis, MD ‐1.30; 95% CI ‐2.32 to ‐0.28, P = 0.01, 1 study).</p> </li> </ul> </p> </section> <section id="CD001191-sec-0093"> <h5 class="title">Activities of daily living</h5> <p>The ADCS‐ADL showed benefit in favour of rivastigmine at 24 weeks (ITT analysis, MD 2.20; 95% CI 0.62 to 3.78, P = 0.006, 1 study). </p> <p>The DAD showed benefit in favour of rivastigmine at 24 weeks (ITT analysis, MD 2.3; 95% CI 0.34 to 4.26, P = 0.02, 1 study). </p> </section> <section id="CD001191-sec-0094"> <h5 class="title">Global assessment</h5> <p>The seven‐point CIBIC‐Plus scale measuring global clinical state was dichotomized by counting those showing no change or decline against those showing improvement and analysed using the Peto OR. There was no difference between rivastigmine and placebo at 24 weeks (382/518 rivastigmine, 426/545 placebo) (ITT analysis, OR 0.77; 95% CI 0.58 to 1.02, P = 0.07, 2 studies). </p> </section> <section id="CD001191-sec-0095"> <h5 class="title">Withdrawals before the end of treatment</h5> <p>There was a significant difference between rivastigmine and placebo in favour of placebo for total withdrawals before the end of treatment (123/580 rivastigmine compared with 82/590 placebo) (OR 1.67; 95% CI 1.23 to 2.26, P = 0.001, 2 studies). </p> </section> <section id="CD001191-sec-0096"> <h5 class="title">Adverse events</h5> <p>There were significant differences between rivastigmine and placebo in favour of placebo for the total number of patients that had at least one adverse event by 24 weeks (395/578 rivastigmine compared with 361/588 placebo) (OR 1.39; 95% CI 1.08 to 1.80, P = 0.01, 2 studies) and withdrawals due to adverse events (62/580 rivastigmine compared with 36/590 placebo) (OR 1.84; 95% CI 1.20 to 2.82, P = 0.005, 2 studies). </p> <p>There were significant differences between rivastigmine and placebo in favour of placebo for the total number of patients that had at least one adverse event at the application site: erythema (113/287 compared with 55/286) (OR 2.73; 95% CI 1.87 to 3.98, P &lt; 0.00001, 1 study), application site pruritis (100/287 compared with 61/286) (OR 1.97; 95% CI 1.36 to 2.86, P = 0.0004, 1 study), application site oedema (31/287 compared with 7/286) (OR 4.83; 95% CI 2.09 to 11.15, P = 0.0002, 1 study), application site exfoliation (11/282 compared with 4/286) (OR 3.68; 95% CI 1.20 to 1.33, P = 0.02), contact dermatitis (68/287 compared with 40/286) (OR 1.91; 95% CI 1.24 to 2.94, P = 0.003, 1 study), nausea (41/578 compared with 24/588) (OR 1.80; 95% CI 1.07 to 3.02, P = 0.03, 2 studies) and vomiting (41/578 compared with 21/588) (OR 2.06; 95% CI 1.20 to 3.53, P = 0.009, 2 studies). </p> </section> <section id="CD001191-sec-0097"> <h5 class="title">Withdrawals before the end of treatment due to adverse events</h5> <p>There was a significant difference between rivastigmine and placebo in favour of placebo for withdrawals due to adverse events (62/580 rivastigmine compared with 36/590 placebo) (OR 1.84; 95% CI 1.20 to 2.82, P = 0.005, 2 studies). </p> </section> </section> <section id="CD001191-sec-0098"> <h4 class="title">Comparison of rivastigmine (5 cm<sup>2</sup> (4.6 mg/day) patch) with placebo </h4> <p>This comparison was made in one study (<a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a>). </p> <section id="CD001191-sec-0099"> <h5 class="title">Cognitive function</h5> <p>There was no difference between rivastigmine and placebo at 24 weeks for cognitive function measured using the ADAS‐Cog scale (ITT analysis, MD 0.80; 95% CI ‐1.62 to 0.02), MMSE ITT analysis, MD 0.00; 95% CI ‐0.52 to 0.52) and MENFIS (ITT analysis, MD ‐0.70; 95% CI ‐0.70, 95% CI ‐1.72 to 0.32). </p> </section> <section id="CD001191-sec-0100"> <h5 class="title">Activities of daily living</h5> <p>There was no difference between rivastigmine and placebo at 24 weeks for activities of daily living measured using the DAD scale (ITT analysis, MD 1.20; 95% CI ‐0.73 to 3.13). </p> </section> <section id="CD001191-sec-0101"> <h5 class="title">Global assessment</h5> <p>There was no difference between rivastigmine and placebo at 24 weeks for global assessment measured using the CIBIC‐plus J scale (212/269 rivastigmine, 226/267 placebo) (ITT analysis, OR 0.67; 95% CI 0.43 to 1.05). </p> </section> <section id="CD001191-sec-0102"> <h5 class="title">Behavioural symptoms</h5> <p>There was no difference between rivastigmine and placebo at 24 weeks for behavioural symptoms measured using the BEHAVE‐AD scale (ITT analysis, MD 0.00; 95% CI ‐0.67 to 0.67). </p> </section> <section id="CD001191-sec-0103"> <h5 class="title">Withdrawals before the end of treatment</h5> <p>There was a significant difference between rivastigmine and placebo in favour of placebo for total withdrawals before the end of treatment (64/284 rivastigmine compared with 46/288 placebo) (OR 1.53; 95% CI 1.01 to 2.33, P = 0.05). </p> </section> <section id="CD001191-sec-0104"> <h5 class="title">Adverse events</h5> <p>There was a significant difference between rivastigmine and placebo in favour of placebo for the total number of patients that had at least one adverse event at 24 weeks (243/282 rivastigmine compared with 222/286 placebo) (OR 1.80; 95% CI 1.16 to 2.78, P = 0.009), but no difference for deaths. </p> <p>There were significant differences between rivastigmine and placebo in favour of placebo for the total number of patients that had at least one adverse event at the application site: erythema (106/282 compared with 55/286) (OR 2.53; 95% CI 1.73 to 3.70, P &lt; 0.00001, 1 study), application site pruritis (92/282 compared with 61/286) (OR 1.79; 95% CI 1.23 to 2.60, P = 0.003, 1 study), application site oedema (35/282 compared with 7/286) (OR 5.65; 95% CI 2.46 to 12.94, P &lt; 0.0001, 1 study), application site exfoliation (14/282 compared with 4/286) (OR 3.68; 95% CI 1.20 to 11.35, P = 0.02), contact dermatitis (69/282 compared with 40/286) (OR 1.99; 95% CI 1.30 to 3.06, P = 0.002, 1 study); but no difference between rivastigmine and placebo for adverse events of nasopharyngitis, nausea, vomiting and diarrhoea. </p> </section> <section id="CD001191-sec-0105"> <h5 class="title">Withdrawals before the end of treatment due to adverse events</h5> <p>There was a significant difference between rivastigmine and placebo in favour of placebo for withdrawals due to adverse events (38/284 rivastigmine compared with 21/288 placebo) (OR 1.96; 95% CI 1.12 to 3.44, P = 0.02). </p> </section> </section> <section id="CD001191-sec-0106"> <h4 class="title">Comparison of rivastigmine (10 cm<sup>2</sup> (9.5 mg/day) patch) with rivastigmine (6 to 12 mg/day twice daily) capsules </h4> <section id="CD001191-sec-0107"> <h5 class="title">Cognitive function</h5> <p>One study (<a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>) showed no difference between the rivastigmine patch and rivastigmine capsules on cognitive function as measured by the ADAS‐Cog, MMSE, TMT‐A and MENFIS at 24 weeks: </p> <p> <ul id="CD001191-list-0039"> <li> <p>ADAS‐cog (ITT analysis, MD 0.0; 95% CI ‐1.10 to 1.10, P = 1.0, 1 study);</p> </li> <li> <p>MMSE (ITT analysis, MD 0.30; 95% CI ‐0.27 to 0.87, P = 0.30, 1 study);</p> </li> <li> <p>TMT‐A (ITT analysis, MD ‐2.6; 95% CI ‐13.5 to 8.3, P = 0.64, 1 study);</p> </li> <li> <p>clock drawing (ITT analysis, MD 0.1; 95% CI ‐0.5 to 0.7, P = 0.73, 1 study).</p> </li> </ul> </p> </section> <section id="CD001191-sec-0108"> <h5 class="title">Activities of daily living</h5> <p>The ADCS‐ADL showed no difference between the rivastigmine patch and rivastigmine capsules at 24 weeks (ITT analysis, MD 0.40; 95% CI ‐1.23 to 2.03, P = 0.63, 1 study). </p> </section> <section id="CD001191-sec-0109"> <h5 class="title">Global assessment</h5> <p>The seven‐point CIBIC‐Plus scale measuring global clinical state was dichotomized by counting those showing no change or decline against those showing improvement and analysed using the Peto OR. There was no difference between the rivastigmine patch and rivastigmine capsules at 24 weeks (171/248 rivastigmine patch, 161/267253 rivastigmine capsules) (ITT analysis, OR 1.27; 95% CI 0.88 to 1.84, P = 0.21, 1 study). </p> </section> <section id="CD001191-sec-0110"> <h5 class="title">Behavioural symptoms</h5> <p>One study assessed behavioural symptoms using the NPI (NPI‐12). There was no difference between the rivastigmine patch and rivastigmine capsules (ITT analysis, MD 0.50; 95% CI ‐1.55 to 2.55, P = 0.63, 1 study). </p> </section> <section id="CD001191-sec-0111"> <h5 class="title">Withdrawals before the end of treatment</h5> <p>There was no significant difference between rivastigmine and placebo for withdrawals before the end of treatment (64/293 compared with 63/297) (OR 1.09; 95% CI 0.70 to 154, P = 0.85, 1 study). </p> </section> <section id="CD001191-sec-0112"> <h5 class="title">Adverse events</h5> <p>There was a significant difference between the rivastigmine patch and rivastigmine capsules in favour of the patch for the total number of patients that had at least one adverse event by 24 weeks (147/291 rivastigmine compared with 186/294 placebo) (OR 0.59; 95% CI 0.43 to 0.82, P = 0.002, 1 study). </p> <p>There were significant differences between the rivastigmine patch and rivastigmine capsules in favour of the patch for the total number of patients that had at least one adverse event of decreased appetite (2/291 compared with 12/294) (OR 0.16; 95% CI 0.04 to 0.73, P = 0.02, 1 study), dizziness (7/291 compared with 22/294) (OR 0.30; 95% CI 0.13 to 0.72, P = 0.007, 1 study), asthenia (5/291 compared with 17/294) (OR 0.28; 95% CI 0.10 to 0.78, P = 0.01, 1 study), nausea (21/291 compared with 68/294) (OR 0.26; 95% CI 0.15 to 0.43, P &lt; 0.001, 1 study) and vomiting (18/291 compared with 50/294) (OR 0.32; 95% CI 0.18 to 0.57, P &lt; 0.001, 1 study). </p> </section> <section id="CD001191-sec-0113"> <h5 class="title">Withdrawals before the end of treatment due to adverse events</h5> <p>There was no significant difference between rivastigmine and placebo for withdrawals due to adverse events (28/293 rivastigmine compared with 24/297 placebo) (OR 1.20; 95% CI 0.68 to 2.13, P = 0.53, 1 study). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001191-sec-0114" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001191-sec-0114"></div> <section id="CD001191-sec-0115"> <h3 class="title" id="CD001191-sec-0115">Summary of main results</h3> <p>The results of the review showed the following main findings.</p> <p> <ul id="CD001191-list-0040"> <li> <p>The currently recommended doses of rivastigmine (6 to 12 mg/day in two divided doses for capsules and 9.5 mg/day for transdermal patches) have some benefits compared to placebo at 26 weeks for cognitive function, activities of daily living and the physician rated global impression scales. No difference was found for behavioural symptoms or the impact on carers. Patients on rivastigmine are about twice as likely (OR of about 2) to experience adverse events or to withdraw from the trial before the end of the study. </p> </li> <li> <p>Limited evidence from one trial suggests that the transdermal formulation (9.5 mg/day) is as effective as the oral formulation (6 to 12 mg/day) and is associated with a lower incidence of adverse events but does not affect the rate of withdrawals due to adverse events. </p> </li> </ul> </p> <section id="CD001191-sec-0116"> <h4 class="title">Outcomes</h4> <p>The two cognitive tests used, the MMSE and ADAS‐Cog, assess similar domains and a high correlation between the results would be expected. The results from 5 studies show that 6 to 12 mg daily of oral rivastigmine improved the cognitive function of patients with mild to moderate probable Alzheimer's disease treated over a period of 26 weeks, by 0.8 points on the MMSE (range 0 to 30) and by 2.0 points on the ADAS‐Cog (range 0 to 70), when compared with placebo. The results from 2 studies show that the 9.5 mg/day of rivastigmine in a transdermal patch improved cognitive function by 0.6 points on the MMSE and 1.4 points on the ADAS‐cog when compared with placebo. Pooling the data showed a treatment effect of 0.7 points on the MMSE and 1.8 points on the ADAS‐Cog. There was a smaller effect on cognitive function in the 1 to 4 mg daily oral treatment group. </p> <p>Four studies assessed the effect of 6 to 12 mg daily oral rivastigmine on activities of daily living as reported by a carer using the PDS rating scale (range 0 to 100). Rivastigmine showed a benefit of 2.2 points compared with placebo, but the difference between placebo and 1 to 4 mg daily rivastigmine was not significant. The 10 cm<sup>2</sup> (9.5 mg/day) patch showed a benefit of 2.2 points on the ADCS‐ADL scale (range 0 to 54) when compared with placebo. </p> <p>The US Food and Drug Administration (FDA) requires an independent clinician to assess global clinical state after interviewing the patient and the carer at baseline and the endpoint. When the results of global impression measures were dichotomized to compare the number of patients who improved with the numbers who showed no change or whose condition had deteriorated, the 6 to 12 mg daily group was significantly better than the placebo group at 12 and 26 weeks, and there was a similar significant difference favouring the 1 to 4 mg daily group over placebo at 26 weeks. The 10 cm<sup>2</sup> (9.5 mg/day) patch was also significantly better than placebo at 24 weeks.The clinician and carer, whilst following the guidelines for the application of the CIBIC‐Plus, are essentially making an assessment of whether the patient has improved or not based on criteria relevant to them. This is perhaps closest to what is commonly meant by the term 'meaningful improvement'. </p> <p>Minimal clinically important differences (MCID), patient derived scores that represent changes in a score that have meaning for patients, have been suggested for the ADAS‐cog (3 points in severe AD (<a href="./references#CD001191-bbs2-0082" title="HowardR , PhillipsP , JohnsonT , O’BrienJ , SheehanB , LindesayJ , et al. Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry2011;26(8):812‐7. ">Howard 2011</a>)) and MMSE (1.4 points in mild AD (<a href="./references#CD001191-bbs2-0097" title="SchragA , SchottJM , Alzheimer's Disease Neuroimaging Initiative. Research paper: What is the clinically relevant change on the ADAS‐Cog?. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(2):171‐3. ">Schrag 2012</a>)). Comparing our findings with these we might conclude that the treatment effects for cognitive function are unlikely to be clinically relevant. </p> </section> <section id="CD001191-sec-0117"> <h4 class="title">Adverse effects</h4> <p>When taking capsules, a fairly lengthy titration period of up to 12 weeks is needed to develop tolerance and to minimize adverse effects such as nausea, vomiting, diarrhoea, abdominal pain, dizziness, headache and anorexia. The target was to treat patients with a maximum tolerated dose administered in two divided doses, the upper limit being 12 mg per day. There were significantly more total dropouts and dropouts due to adverse events from the 6 to 12 mg daily dose groups than from placebo groups and therefore adverse effects remain a clinical issue. There was no hepatotoxicity associated with rivastigmine and no statistically or clinically significant changes in vital signs. </p> <p>The continuous dose patch was introduced to improve tolerability. One study (<a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>) tested two sizes of rivastigmine patch, one delivering a higher dose than previously tested in a 20 cm<sup>2</sup> patch (17.4 mg/day) and one 10 cm<sup>2</sup> patch (9.5 mg/day), a dose similar to the usual oral dose. Another study (<a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a>) tested 5 cm<sup>2</sup> (4.6 mg/day) and 10 cm<sup>2</sup> (9.5 mg/day) patches. The smallest patch showed no treatment effect when compared with placebo for cognition, global function and activities of daily living. The efficacy of the 9.5 mg/day patch was comparable to that of the capsules with a similar daily dose, but was associated with significantly fewer adverse events of nausea, vomiting, dizziness and asthenia. There was no difference in the number of withdrawals due to adverse events. Therefore, the 9.5 mg/day patch appears to have advantages compared with both the higher dose patches and the 6 to 12 mg/day capsules in terms of the overall incidence of adverse events, but it may not reduce the incidence of the more serious events that lead to cessation of treatment. </p> </section> </section> <section id="CD001191-sec-0118"> <h3 class="title" id="CD001191-sec-0118">Overall completeness and applicability of evidence</h3> <p>We were able to include evidence from both published and unpublished trials in this systematic review. There were 3319 participants. Most participants were in industry sponsored trials. Data from two independent trials (n = 162) were not available and we excluded data from two other independent trials (n = 75) from our analyses because of concerns about risk of bias. The participants in the included trials had mainly mild to moderate dementia due to Alzheimer's disease. They were not highly selected with respect to their general health so that all but the seriously ill were included. Only two trials included patients with severe dementia, and we excluded the data from one of these leaving data on only 218 patients with severe dementia included in the analyses. </p> <p>The main limitations in the completeness and applicability of the evidence were the lack of long term data beyond 26 weeks and the limited range of outcomes measured. Beyond 26 weeks, some trials continued as an open label, extension phase. There were very few data on outcomes important to patients and carers, such as quality of life. </p> </section> <section id="CD001191-sec-0119"> <h3 class="title" id="CD001191-sec-0119">Quality of the evidence</h3> <p>The quality of the evidence at 26 weeks is moderate for most outcomes. Our main concern for the evidence is that only seven studies have contributed data to the meta‐analysis, and all of these studies were either industry sponsored or industry funded. In addition, withdrawals from these studies were of concern. </p> <p>The results from <a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a> nearly always showed greater benefits for rivastigmine on each outcome than demonstrated in <a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] ">B303/B305</a>, <a href="./references#CD001191-bbs2-0004" title="FeldmanHH , LaneR . Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry2007;78(10):1056‐63. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B304</a> and <a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a>. <a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a> was responsible for the heterogeneity between trials that was reported for some of the measures of cognitive function. There are no obvious differences between <a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a> and the other phase III trials. It was conducted only in the US, but so was <a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a>. The doses reached by patients in <a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a> were higher than those of <a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a>, by 1.2 mg per day on average. Results from <a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a> have been more extensively reported than the other three phase III trials but there is no reason to suppose that this trial is of any more importance in the overall assessment of rivastigmine. We have not downgraded the evidence based on this heterogeneity concern since the impact on the overall pooled results is small and does not change the interpretation of any of the results. </p> <p>Outcomes such as behavioural symptoms and quality of life are important to patients but these were only reported by three studies and one study, respectively. Hence, the quality of evidence for these was lower. </p> </section> <section id="CD001191-sec-0120"> <h3 class="title" id="CD001191-sec-0120">Potential biases in the review process</h3> <p>The initial protocol of the review, which was published in 1998, had aimed to include all double‐blinded randomised controlled trials (RCTs) of rivastigmine with a minimum study period of two weeks, regardless of the doses or formulations used. However, this resulted in a large number of possible comparisons. In addition, studies often used multiple instruments to report the same outcome, for example cognitive function was measured using the MMSE, ADAS‐Cog and other tests. For some of these outcomes we decided to use only the most commonly used tests in the main analysis. </p> <p>In this update we decided to concentrate on the currently recommended doses (6 and 12 mg/day for oral doses, and 9.5 mg/day for transdermal patches), and a minimum treatment duration of six months for the main analysis. We considered the decision to focus on longer term data was clinically sensible since a titration period was required to reach the target doses. </p> <p><a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a>, <a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a>, <a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a> and <a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a>, all non‐industry funded studies, did not provide data that could be included in the review. </p> </section> <section id="CD001191-sec-0121"> <h3 class="title" id="CD001191-sec-0121">Agreements and disagreements with other studies or reviews</h3> <p>Most patients from the four phase III trials continued in an open label phase for a further 26 weeks during which the maximum tolerated dose was administered. Results from these extension phases have been described as showing a possible beneficial effect of rivastigmine on disease progression (Product monograph, <a href="./references#CD001191-bbs2-0086" title="Novartis Pharmaceutical (UK)Limited . EXELON (rivastigmine) Beyond cognition: prolonging functional ability. Product monograph. EXELON (rivastigmine) Beyond cognition: prolonging functional ability. Product monograph. Frimley, 1998. ">Novartis 1998</a>). Reported results showed that patients who had received placebo or rivastigmine 1 to 4 mg daily in the randomised phase showed initial improvement on the ADAS‐Cog before declining at the same rate as the 6 to 12 mg daily group, although remaining more impaired by approximately 1.5 points. These results must be interpreted with caution. The randomised, double‐blind conditions no longer prevailed. There had been differential dropout from the groups and there was no placebo group for the comparison. An imputed rate of decline for placebo patients was obtained by extrapolating from the randomised phase and not from actual observations. </p> <p>There is much interest in the identification of patient characteristics that might predict a response to a cholinesterase inhibitor. <a href="./references#CD001191-bbs2-0062" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ">Burns 2004</a> reported that cholinesterase inhibitors may be effective in patients with more severe disease. Data were pooled from three studies (<a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] ">B303/B305</a>; <a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a>; <a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a>) for those with a baseline MMSE of 10, 11 or 12 (n = 117), in the group treated with rivastigmine (6 to 12 mg/day) or placebo, and the analysis showed that rivastigmine benefited those with more severe disease. This result has not added anything substantial to what was known already. The analysis of the total dataset from these trials demonstrated that rivastigmine was of benefit to the population randomised. </p> <p><a href="./references#CD001191-bbs2-0068" title="ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56:791‐6. ">Erkinjuntti 2002</a>, funded by Novartis Pharmaceuticals, investigated the response to rivastigmine of those without hypertension compared to those with using the data from <a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] ">B303/B305</a>. They reported that particular benefits may be observed in those with vascular risk factors. These results are based on retrospective analysis of the study data and there has been no study confirming this finding using prospective data. </p> <p><a href="./references#CD001191-bbs2-0069" title="FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003a;60(6):843‐8. ">Farlow 2003a</a> retrieved dropouts from the studies <a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] ">B303/B305</a>, <a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a> and <a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a>. These patients stopped treatment before the end of the trials but were invited back for assessment at the endpoint. Farlow concluded that those who had been in the rivastigmine groups had deteriorated less than those from the placebo groups, and therefore rivastigmine had provided a beneficial delay in disease progression. The two groups cannot be compared. The participants belong to a highly selected group, those who stopped treatment and agreed to return. The placebo group was much smaller than the rivastigmine group (38 compared with 88). Those who left the trial from the placebo group may have done so because their illness was more severe. This may have applied to some of those in the rivastigmine group who left but, in addition, there were those who left because they suffered from adverse effects. It is not possible to compare these two groups in a meaningful way. </p> <p><a href="./references#CD001191-bbs2-0075" title="GrossbergGT , StahelinHB , MessinaJC , AnandR , VeachJ . Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty‐two classes of medications. International Journal of Geriatric Psychiatry2000;15:242‐7. ">Grossberg 2000</a> was a Novartis funded extension study examining the data from the four phase III studies and the related open label extension studies. Those who had been taking rivastigmine continuously for two years were compared with historical controls and the study concluded that rivastigmine has a beneficial effect on cognitive performance for up to two years in patients with Alzheimer's disease. These results must be treated with caution as the two groups are not comparable. </p> <p>Several reviews of rivastigmine have been published. <a href="./references#CD001191-bbs2-0096" title="SchneiderLS , AnandR , FarlowMR . Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:S26‐S34. ">Schneider 1998</a> and <a href="./references#CD001191-bbs2-0099" title="SpencerCM , NobleS . Rivastigmine. A review of its use in Alzheimer's disease. Drugs &amp; Aging1998;13(5):391‐411. ">Spencer 1998</a> both limited analysis and interpretation to the three trials <a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a>, <a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] ">B303/B305</a> and <a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a>. Spencer reported that "individual and pooled results indicate that rivastigmine usually produces cognitive, global and functional changes that indicate significantly less deterioration than was observed with placebo". Schneider reported that "the pooled analyses confirm the efficacy of rivastigmine in the treatment of both the cognitive and functional deficits of mild to moderately severe AD". <a href="./references#CD001191-bbs2-0063" title="CleggA , BryantJ , NicholsonT , McIntyreL , DeBroeS , GerardK , WaughN . Clinical and cost‐effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease: a systematic review. International Journal of Technology Assessment in Health Care2002;18(3):497‐507. ">Clegg 2002</a> was the report from NICE (National Institute of Clinical Excellence, UK) of the systematic review on which the decision was made that the cholinesterase inhibitors would be available on the National Health Service to treat those with Alzheimer's disease. <a href="./references#CD001191-bbs2-0102" title="WilliamsBR , NazariansA , GillMA . A review of rivastigmine: a reversible cholinesterase inhibitor. Clinical Therapeutics2003;25(6):1634‐53. ">Williams 2003</a> was a review of all aspects of rivastigmine, and summarised the clinical trials but without meta‐analyses. </p> <p><a href="./references#CD001191-bbs2-0078" title="HauberAB , GnanasakthyA , MauskopfJA . Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Clinical Therapeutics2000;22(4):439‐51. ">Hauber 2000</a> calculated the potential savings costs using rivastigmine compared with no treatment for Alzheimer's disease. Hauber used a disease stage model. Results from two phase III trials of rivastigmine, together with extrapolation beyond the six month duration of the trial, identified the stage of disease using the MMSE assessments. Costs of healthcare resource use was estimated as a function of MMSE, using data from Canadian sources. Rivastigmine was judged to be cost effective due to the delay in disease progression. The analysis was repeated in a UK and US setting. These results are not based on randomised evidence and rest on many assumptions. It would be unwise to base decisions on whether rivastigmine should be prescribed to patients on the basis of cost‐effectiveness studies such as these. <a href="./references#CD001191-bbs2-0070" title="FillitH , HillJ . The economic benefits of acetylcholinesterase inhibitors for patients with alzheimer disease and associated dementias. Alzheimer Disease and Associated Disorders2004;18 Suppl 1:S24‐9. ">Fillit 2004</a> presents an excellent summary of the cost‐effectiveness studies and of the assumptions on which they are based. Fillit concludes that the results from these studies are not reliable and that outcomes related to costs and healthcare resource use must be assessed in randomised clinical trials. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001191-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001191-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001191-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm2 (9.5 mg/day) patch) versus placebo, Outcome 1 ADAS‐Cog (change from baseline at 24‐26 weeks) ITT." data-id="CD001191-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm<sup>2</sup> (9.5 mg/day) patch) versus placebo, Outcome 1 ADAS‐Cog (change from baseline at 24‐26 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm2 (9.5 mg/day) patch) versus placebo, Outcome 2 MMSE (change from baseline at 24‐26 weeks) ITT." data-id="CD001191-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm<sup>2</sup> (9.5 mg/day) patch) versus placebo, Outcome 2 MMSE (change from baseline at 24‐26 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm2 (9.5 mg/day) patch) versus placebo, Outcome 3 Activities of daily living (change from baseline at 24‐26 weeks ) ITT." data-id="CD001191-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm<sup>2</sup> (9.5 mg/day) patch) versus placebo, Outcome 3 Activities of daily living (change from baseline at 24‐26 weeks ) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm2 (9.5 mg/day) patch) versus placebo, Outcome 4 Clinical Global Impression (no change or worse at 24‐26 weeks ) ITT." data-id="CD001191-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm<sup>2</sup> (9.5 mg/day) patch) versus placebo, Outcome 4 Clinical Global Impression (no change or worse at 24‐26 weeks ) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm2 (9.5 mg/day) patch) versus placebo, Outcome 5 Behavioural symptoms (change from baseline at 24‐26 weeks) ITT." data-id="CD001191-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm<sup>2</sup> (9.5 mg/day) patch) versus placebo, Outcome 5 Behavioural symptoms (change from baseline at 24‐26 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm2 (9.5 mg/day) patch) versus placebo, Outcome 6 Withdrawals before end of treatment at 24‐26 weeks." data-id="CD001191-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm<sup>2</sup> (9.5 mg/day) patch) versus placebo, Outcome 6 Withdrawals before end of treatment at 24‐26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm2 (9.5 mg/day) patch) versus placebo, Outcome 7 at least one adverse event by 24‐26 weeks." data-id="CD001191-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm<sup>2</sup> (9.5 mg/day) patch) versus placebo, Outcome 7 at least one adverse event by 24‐26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm2 (9.5 mg/day) patch) versus placebo, Outcome 8 NPI‐D carer distress scale (change from baseline at 24‐26 weeks) ITT." data-id="CD001191-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm<sup>2</sup> (9.5 mg/day) patch) versus placebo, Outcome 8 NPI‐D carer distress scale (change from baseline at 24‐26 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 1 ADAS‐Cog (change from baseline at 12 weeks) ITT." data-id="CD001191-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 1 ADAS‐Cog (change from baseline at 12 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 2 ADAS‐Cog (change from baseline at 26 weeks) ITT." data-id="CD001191-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 2 ADAS‐Cog (change from baseline at 26 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 3 MMSE (change from baseline at 26 weeks) ITT." data-id="CD001191-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 3 MMSE (change from baseline at 26 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 4 SIB (change from baseline at 26 weeks)." data-id="CD001191-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 4 SIB (change from baseline at 26 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 5 ADCS‐ADL (change from baseline at 26 weeks) ITT." data-id="CD001191-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 5 ADCS‐ADL (change from baseline at 26 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 6 PDS (change from baseline at 12 weeks ) ITT." data-id="CD001191-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 6 PDS (change from baseline at 12 weeks ) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 7 PDS (change from baseline at 26 weeks ) ITT." data-id="CD001191-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 7 PDS (change from baseline at 26 weeks ) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 8 Clinical Global Impression (no change or worse at 12 weeks) ITT." data-id="CD001191-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 8 Clinical Global Impression (no change or worse at 12 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 9 Clinical Global Impression (no change or worse at 26 weeks ) ITT." data-id="CD001191-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 9 Clinical Global Impression (no change or worse at 26 weeks ) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 10 GDS( moderately severe, severe, or very severe dementia at 26 weeks) ITT." data-id="CD001191-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 10 GDS( moderately severe, severe, or very severe dementia at 26 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 11 CGIC (little or no improvement, or worse at 12 weeks) ITT." data-id="CD001191-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 11 CGIC (little or no improvement, or worse at 12 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 12 Behavioural disturbance NPI‐10 or NPI‐12 (change from baseline at 26 weeks) ITT." data-id="CD001191-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 12 Behavioural disturbance NPI‐10 or NPI‐12 (change from baseline at 26 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 13 withdrawals before end of treatment at 12 weeks." data-id="CD001191-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 13 withdrawals before end of treatment at 12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 14 withdrawals before end of treatment at 26 weeks." data-id="CD001191-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 14 withdrawals before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 15 at least one adverse event by the end of titration period." data-id="CD001191-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 15 at least one adverse event by the end of titration period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 16 at least one adverse event by 26 weeks." data-id="CD001191-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 16 at least one adverse event by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 17 dropouts due to adverse events by 12 weeks." data-id="CD001191-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 17 dropouts due to adverse events by 12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 18 dropouts due to adverse events by 26 weeks." data-id="CD001191-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 18 dropouts due to adverse events by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 19 at least one adverse event of decreased appetite by 26 weeks." data-id="CD001191-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 19 at least one adverse event of decreased appetite by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 20 at least one adverse event of weight decrease by 26 weeks." data-id="CD001191-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 20 at least one adverse event of weight decrease by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 21 at least one adverse event of nausea by the end of titration period." data-id="CD001191-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 21 at least one adverse event of nausea by the end of titration period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 22 at least one adverse event of nausea by 26 weeks." data-id="CD001191-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 22 at least one adverse event of nausea by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 23 at least one adverse event of vomiting by the end of titration period." data-id="CD001191-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 23 at least one adverse event of vomiting by the end of titration period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 24 at least one adverse event of vomiting by 26 weeks." data-id="CD001191-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 24 at least one adverse event of vomiting by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 25 at least one adverse event of diarrhoea by the end of titration period." data-id="CD001191-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 25 at least one adverse event of diarrhoea by the end of titration period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 26 at least one adverse event of diarrhoea by 26 weeks." data-id="CD001191-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 26 at least one adverse event of diarrhoea by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 27 at least one adverse event of anorexia by the end of titration period." data-id="CD001191-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 27 at least one adverse event of anorexia by the end of titration period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 28 at least one adverse event of anorexia by 26 weeks." data-id="CD001191-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 28 at least one adverse event of anorexia by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 29 at least one adverse event of headache by the end of titration period." data-id="CD001191-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.29</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 29 at least one adverse event of headache by the end of titration period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 30 at least one adverse event of headache by 26 weeks." data-id="CD001191-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.30</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 30 at least one adverse event of headache by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 31 at least one adverse event of insomnia by the end of titration period." data-id="CD001191-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.31</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 31 at least one adverse event of insomnia by the end of titration period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 32 at least one adverse event of insomnia by 26 weeks." data-id="CD001191-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.32</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 32 at least one adverse event of insomnia by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 33 at least one adverse event of syncope by the end of titration period." data-id="CD001191-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.33</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 33 at least one adverse event of syncope by the end of titration period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 34 at least one adverse event of syncope by 26 weeks." data-id="CD001191-fig-0044" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.34</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 34 at least one adverse event of syncope by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 35 at least one adverse event of abdominal pain by the end of titration period." data-id="CD001191-fig-0045" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.35</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 35 at least one adverse event of abdominal pain by the end of titration period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 36 at least one adverse event of abdominal pain by 26 weeks." data-id="CD001191-fig-0046" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.36</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 36 at least one adverse event of abdominal pain by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 37 at least one adverse event of dizziness by the end of titration period." data-id="CD001191-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.37</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 37 at least one adverse event of dizziness by the end of titration period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 38 at least one adverse event of dizziness by 26 weeks." data-id="CD001191-fig-0048" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.38</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 38 at least one adverse event of dizziness by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 39 at least one adverse event of bone fracture by the end of titration period." data-id="CD001191-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.39</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 39 at least one adverse event of bone fracture by the end of titration period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 40 at least one adverse event of bone fracture by 26 weeks." data-id="CD001191-fig-0050" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.40</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 40 at least one adverse event of bone fracture by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 41 at least one adverse event of asthenia by 26 weeks." data-id="CD001191-fig-0051" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.41</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 41 at least one adverse event of asthenia by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 42 at least one severe adverse event by the end of titration period." data-id="CD001191-fig-0052" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.42</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 42 at least one severe adverse event by the end of titration period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 43 at least one serious adverse event by 26 weeks." data-id="CD001191-fig-0053" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.43</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 43 at least one serious adverse event by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 44 deaths before end of treatment at 12 weeks." data-id="CD001191-fig-0054" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.44</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 44 deaths before end of treatment at 12 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 45 deaths before end of treatment at 26 weeks." data-id="CD001191-fig-0055" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.45</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 45 deaths before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-46.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 46 CIBIC‐Plus (no change or worse at 12 weeks) OC." data-id="CD001191-fig-0056" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.46</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 46 CIBIC‐Plus (no change or worse at 12 weeks) OC. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-47" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-47.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 47 CIBIC‐Plus (no change or worse at 26 weeks) OC." data-id="CD001191-fig-0057" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-47.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.47</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 47 CIBIC‐Plus (no change or worse at 26 weeks) OC. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-47.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-48" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-48.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 48 CIBIC‐Plus (no change or worse at 12 weeks) OC+RDO." data-id="CD001191-fig-0058" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-48.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.48</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 48 CIBIC‐Plus (no change or worse at 12 weeks) OC+RDO. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-48.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-49" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-49.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 49 CIBIC‐Plus (no change or worse at 26 weeks)OC+RDO." data-id="CD001191-fig-0059" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-49.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.49</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 49 CIBIC‐Plus (no change or worse at 26 weeks)OC+RDO. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-49.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-50" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-50.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 50 CIBIC‐Plus (no change or worse at 12 weeks) ALL+OC." data-id="CD001191-fig-0060" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-50.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.50</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 50 CIBIC‐Plus (no change or worse at 12 weeks) ALL+OC. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-50.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-51" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-51.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 51 CIBIC‐Plus (no change or worse at 26 weeks) ALL+OC." data-id="CD001191-fig-0061" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-51.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.51</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 51 CIBIC‐Plus (no change or worse at 26 weeks) ALL+OC. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-51.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-52" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-52.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 52 ADAS‐Cog (change from baseline at 12 weeks) OC." data-id="CD001191-fig-0062" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-52.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.52</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 52 ADAS‐Cog (change from baseline at 12 weeks) OC. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-52.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-53" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-53.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 53 ADAS‐Cog (change from baseline at 26 weeks) OC." data-id="CD001191-fig-0063" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-53.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.53</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 53 ADAS‐Cog (change from baseline at 26 weeks) OC. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-53.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-54" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-54.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 54 ADAS‐Cog (change from baseline at 12 weeks) OC+RDO." data-id="CD001191-fig-0064" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-54.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.54</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 54 ADAS‐Cog (change from baseline at 12 weeks) OC+RDO. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-54.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-002-55" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-002-55.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 55 ADAS‐Cog (change from baseline at 26 weeks) OC+RDO." data-id="CD001191-fig-0065" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-55.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.55</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo, Outcome 55 ADAS‐Cog (change from baseline at 26 weeks) OC+RDO. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-002-55.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 1 ADAS‐Cog (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0066" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 1 ADAS‐Cog (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 2 TMT‐A (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0067" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 2 TMT‐A (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 3 clock drawing (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0068" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 3 clock drawing (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 4 MMSE (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0069" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 4 MMSE (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 5 ADCS‐ADL (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0070" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 5 ADCS‐ADL (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 6 NPI‐12 (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0071" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 6 NPI‐12 (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 7 withdrawals before end of treatment at 24 weeks." data-id="CD001191-fig-0072" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 7 withdrawals before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 8 at least one adverse event by 24 weeks." data-id="CD001191-fig-0073" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 8 at least one adverse event by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 9 withdrawals due to an adverse event before end of treatment at 24 weeks." data-id="CD001191-fig-0074" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 9 withdrawals due to an adverse event before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 10 at least one adverse event of dizziness by 24 weeks." data-id="CD001191-fig-0075" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 10 at least one adverse event of dizziness by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 11 at least one adverse event of nausea by 24 weeks." data-id="CD001191-fig-0076" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 11 at least one adverse event of nausea by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 12 at least one adverse event of vomiting by 24 weeks." data-id="CD001191-fig-0077" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 12 at least one adverse event of vomiting by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 13 at least one adverse event of weight decrease by 24 weeks." data-id="CD001191-fig-0078" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 13 at least one adverse event of weight decrease by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 14 at least one adverse event of decreased appetite by 24 weeks." data-id="CD001191-fig-0079" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 14 at least one adverse event of decreased appetite by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 15 at least one adverse event of headache by 24 weeks." data-id="CD001191-fig-0080" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 15 at least one adverse event of headache by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 16 at least one adverse event of asthenia by 24 weeks." data-id="CD001191-fig-0081" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 16 at least one adverse event of asthenia by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 17 deaths before end of treatment at 24 weeks." data-id="CD001191-fig-0082" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 17 deaths before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo, Outcome 18 NPI‐D carer distress scale (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0083" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine 20 cm<sup>2</sup> patch (17.4 mg/day) versus placebo, Outcome 18 NPI‐D carer distress scale (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 1 ADAS‐Cog (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0084" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 1 ADAS‐Cog (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 2 MMSE (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0085" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 2 MMSE (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 3 clock drawing (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0086" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 3 clock drawing (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 4 TMT‐A (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0087" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 4 TMT‐A (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 5 Mental Function Impairment MENFIS (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0088" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 5 Mental Function Impairment MENFIS (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 6 ADCS‐ADL (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0089" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 6 ADCS‐ADL (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 7 Disability Assessment for Dementia (DAD) (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0090" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 7 Disability Assessment for Dementia (DAD) (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 8 BEHAVE‐AD (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0091" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 8 BEHAVE‐AD (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 9 NPI‐12 (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0092" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 9 NPI‐12 (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 10 Clinical Global Impression (no change or worse at 24 weeks)." data-id="CD001191-fig-0093" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 10 Clinical Global Impression (no change or worse at 24 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 11 withdrawals before end of treatment at 24 weeks." data-id="CD001191-fig-0094" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 11 withdrawals before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 12 at least one adverse event by 24 weeks." data-id="CD001191-fig-0095" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 12 at least one adverse event by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 13 withdrawals due to an adverse event before end of treatment at 24 weeks." data-id="CD001191-fig-0096" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 13 withdrawals due to an adverse event before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 14 at least one adverse event of application site erythema by 24 weeks." data-id="CD001191-fig-0097" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 14 at least one adverse event of application site erythema by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 15 at least one adverse event of application site pruritis by 24 weeks." data-id="CD001191-fig-0098" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 15 at least one adverse event of application site pruritis by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 16 at least one adverse event of application site edema by 24 weeks." data-id="CD001191-fig-0099" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 16 at least one adverse event of application site edema by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 17 at least one adverse event application site exfoliation by 24 weeks." data-id="CD001191-fig-0100" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 17 at least one adverse event application site exfoliation by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 18 at least one adverse event of dermatitis contact by 24 weeks." data-id="CD001191-fig-0101" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 18 at least one adverse event of dermatitis contact by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 19 at least one adverse event of nasopharyngitis by 24 weeks." data-id="CD001191-fig-0102" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.19</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 19 at least one adverse event of nasopharyngitis by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 20 at least one adverse event of nausea by 24 weeks." data-id="CD001191-fig-0103" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.20</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 20 at least one adverse event of nausea by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 21 at least one adverse event of vomiting by 24 weeks." data-id="CD001191-fig-0104" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.21</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 21 at least one adverse event of vomiting by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 22 at least one adverse event of diarrhoea by 24 weeks." data-id="CD001191-fig-0105" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.22</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 22 at least one adverse event of diarrhoea by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 23 at least one adverse event of weight decrease by 24 weeks." data-id="CD001191-fig-0106" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.23</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 23 at least one adverse event of weight decrease by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 24 at least one adverse event of dizziness by 24 weeks." data-id="CD001191-fig-0107" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.24</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 24 at least one adverse event of dizziness by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 25 at least one adverse event of decreased appetite by 24 weeks." data-id="CD001191-fig-0108" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.25</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 25 at least one adverse event of decreased appetite by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 26 at least one adverse event of headache by 24 weeks." data-id="CD001191-fig-0109" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.26</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 26 at least one adverse event of headache by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 27 at least one adverse event of asthenia by 24 weeks." data-id="CD001191-fig-0110" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.27</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 27 at least one adverse event of asthenia by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 28 deaths before end of treatment at 24 weeks." data-id="CD001191-fig-0111" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.28</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 28 deaths before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-004-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-004-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo, Outcome 29 NPI‐D carer distress scale (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0112" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.29</div> <div class="figure-caption"> <p>Comparison 4 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus placebo, Outcome 29 NPI‐D carer distress scale (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-004-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 1 ADAS‐J Cog (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0113" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 1 ADAS‐J Cog (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 2 MMSE (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0114" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 2 MMSE (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 3 Mental Function Impairment MENFIS (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0115" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 3 Mental Function Impairment MENFIS (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 4 Disability Assessment for Dementia (DAD) (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0116" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 4 Disability Assessment for Dementia (DAD) (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 5 CIBIC‐Plus J (no change or worse at 24 weeks) ITT." data-id="CD001191-fig-0117" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 5 CIBIC‐Plus J (no change or worse at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 6 BEHAVE‐AD (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0118" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 6 BEHAVE‐AD (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 7 withdrawals before end of treatment at 24 weeks." data-id="CD001191-fig-0119" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 7 withdrawals before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 8 at least one adverse event by 24 weeks." data-id="CD001191-fig-0120" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 8 at least one adverse event by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 9 withdrawals due to an adverse event before end of treatment at 24 weeks." data-id="CD001191-fig-0121" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 9 withdrawals due to an adverse event before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 10 at least one adverse event of application site erythema by 24 weeks." data-id="CD001191-fig-0122" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 10 at least one adverse event of application site erythema by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 11 at least one adverse event of application site pruritis by 24 weeks." data-id="CD001191-fig-0123" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 11 at least one adverse event of application site pruritis by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 12 at least one adverse event of application site edema by 24 weeks." data-id="CD001191-fig-0124" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 12 at least one adverse event of application site edema by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 13 at least one adverse event application site exfoliation by 24 weeks." data-id="CD001191-fig-0125" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 13 at least one adverse event application site exfoliation by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 14 at least one adverse event of dermatitis contact by 24 weeks." data-id="CD001191-fig-0126" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 14 at least one adverse event of dermatitis contact by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 15 at least one adverse event of nasopharyngitis by 24 weeks." data-id="CD001191-fig-0127" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 15 at least one adverse event of nasopharyngitis by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 16 at least one adverse event of nausea by 24 weeks." data-id="CD001191-fig-0128" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 16 at least one adverse event of nausea by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 17 at least one adverse event of vomiting by 24 weeks." data-id="CD001191-fig-0129" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 17 at least one adverse event of vomiting by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-005-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-005-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo, Outcome 18 deaths before end of treatment at 24 weeks." data-id="CD001191-fig-0130" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5 Rivastigmine 5 cm<sup>2</sup> patch (4.6 mg/day) versus placebo, Outcome 18 deaths before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-005-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 1 ADAS‐Cog (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0131" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 1 ADAS‐Cog (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 2 MMSE (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0132" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 2 MMSE (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 3 clock drawing (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0133" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 3 clock drawing (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 4 TMT‐A (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0134" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 4 TMT‐A (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 5 ADCS‐ADL (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0135" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 5 ADCS‐ADL (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 6 Clinical Global Impression (no change or worse at 24 weeks)." data-id="CD001191-fig-0136" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 6 Clinical Global Impression (no change or worse at 24 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 7 NPI‐12 (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0137" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 7 NPI‐12 (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 8 withdrawals before end of treatment at 24 weeks." data-id="CD001191-fig-0138" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 8 withdrawals before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 9 at least one adverse event by 24 weeks." data-id="CD001191-fig-0139" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 9 at least one adverse event by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 10 withdrawals due to an adverse event before end of treatment at 24 weeks." data-id="CD001191-fig-0140" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 10 withdrawals due to an adverse event before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 11 at least one adverse event of nausea by 24 weeks." data-id="CD001191-fig-0141" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 11 at least one adverse event of nausea by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 12 at least one adverse event of vomiting by 24 weeks." data-id="CD001191-fig-0142" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 12 at least one adverse event of vomiting by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 13 at least one adverse event of diarrhoea by 24 weeks." data-id="CD001191-fig-0143" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 13 at least one adverse event of diarrhoea by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 14 at least one adverse event of weight decrease by 24 weeks." data-id="CD001191-fig-0144" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 14 at least one adverse event of weight decrease by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 15 at least one adverse event of dizziness by 24 weeks." data-id="CD001191-fig-0145" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 15 at least one adverse event of dizziness by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 16 at least one adverse event of decreased appetite by 24 weeks." data-id="CD001191-fig-0146" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 16 at least one adverse event of decreased appetite by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 17 at least one adverse event of headache by 24 weeks." data-id="CD001191-fig-0147" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.17</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 17 at least one adverse event of headache by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 18 at least one adverse event of asthenia by 24 weeks." data-id="CD001191-fig-0148" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.18</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 18 at least one adverse event of asthenia by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 19 deaths before end of treatment at 24 weeks + 30 days." data-id="CD001191-fig-0149" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.19</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 19 deaths before end of treatment at 24 weeks + 30 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001191-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/urn:x-wiley:14651858:media:CD001191:CD001191-CMP-006-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_t/tCD001191-CMP-006-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 20 NPI‐D carer distress scale (change from baseline at 24 weeks) ITT." data-id="CD001191-fig-0150" src="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.20</div> <div class="figure-caption"> <p>Comparison 6 Rivastigmine 10 cm<sup>2</sup> patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses), Outcome 20 NPI‐D carer distress scale (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/media/CDSR/CD001191/image_n/nCD001191-CMP-006-20.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001191-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Rivastigmine compared to placebo for Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm<sup>2</sup> (9.8 mg/day) patch) compared to placebo for Alzheimer's disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with Alzheimer's disease, mild to moderate<br/> <b>Settings:</b> multicentre, mostly in Europe or United States<br/> <b>Intervention:</b> rivastigmine (capsules 6 to 12 mg/day in 2 divided doses or 10 cm<sup>2</sup> patch) for 24 to 26 weeks<br/> <b>Comparison:</b> placebo for 24 to 26 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Rivastigmine (capsules 6 to 12 mg/day b.i.d. or 10 cm<sup>2</sup> patch)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive function</b> </p> <p>(change from baseline at 26 weeks using ADAS‐Cog)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the rivastigmine group was <b>1.79 lower</b> (2.21 to 1.37 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3232<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2,</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog score has a maximum of 70 points, the lower score of the rivastigmine group indicates greater improvement </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognitive function</b> </p> <p>(change from baseline at 26 weeks using MMSE)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean score in the rivastigmine group was <b>0.74 higher</b> (0.52 to 0.97 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3205 (6 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MMSE has a maximum score of 30 points, a lower score indicates greater impairment. treatment effect was in favour of rivastigmine </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Activities of daily living</b> </p> <p>(change from baseline at 26 weeks measured using various scales)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the rivastigmine group was <b>0.2 standard deviations higher</b><br/> (0.13 to 0.27 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3230<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.2 (0.13 to 0.27)</p> <p>A SMD of 0.2 is considered a small effect size.</p> <p>Treatment effect in favour of rivastigmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Physician rated global impression tests</b> (no change or worse compared with baseline, measured using Global Impression of Change at 26 weeks) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>810 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>744 per 1000</b> (712 to 773) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.68</b> <br/> (0.58 to 0.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3338<br/> (7 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment effect was in favour of rivastigmine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behavioural symptoms</p> <p>(change from baseline at 26 weeks measured using various scales)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the rivastigmine group was<br/> <b>0.04 standard deviations lower</b> (0.14 lower to 0.06 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1529<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.04 (‐0.14 to 0.06)</p> <p>A SMD of 0.2 is considered a small effect size. The size of this SMD and its small confidence interval suggests that there is no difference between the two groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of treatment</b> (as measured by withdrawals from trials before end of treatment at 26 weeks) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>149 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b> (230 to 293) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.01</b> (1.71, 2.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3569<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals significantly more frequent in rivastigmine group compared with placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of adverse events</b> (at least one adverse event by 26 weeks) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>761 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>870 per 1000</b> (850 to 888) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.14</b> </p> <p>(1.80 to 2.53)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3587<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events significantly more frequent in rivastigmine group compared with placebo group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life of patients or carers</b> (measured using NPI‐D carer distress scale (change from baseline at 24 weeks) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the rivastigmine group was <b>0.1 higher</b> (0.91 lower to 1.11 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>529<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The size of this MD and its small confidence interval suggests that there is no difference between the two groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>assumed risk</b> used the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Confidence in estimate of effect lowered due to relatively high dropout rates across studies, which are higher in the treatment group. The ITT analysis in these studies used LOCF (last observed carried forward) imputations. In addition, results are available up to only 26 weeks, longer term data would be more applicable. </p> <p><sup>2</sup> There was high heterogeneity the ADAS‐Cog outcome due to B352, which had high dropout rates and showed a difference of 3.8 points, compared to 1.2 to 1.6 points for the other studies. However, evidence not further downgraded; removal of this study from the analysis will only result in a small change of estimate by about 0.35 points.<br/> <sup>3</sup> Three studies (<a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>; <a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a>; <a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a>) reported a scale measuring behavioural disturbance.<br/> <sup>4</sup> The protocol for most studies had some measures related to quality of life or impact on carers, but only one study reported this (<a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Rivastigmine compared to placebo for Alzheimer's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001191-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of the included studies at baseline</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% males</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean MMSE (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of centres</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment groups</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Oral (different doses versus placebo )</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0001" title="AgidY , Dubois B on behalf of the International Rivastigmine Investigators, AnandR , GharabawiG . Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutic Research1998;59(12):837‐45. AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ">B103</a> </p> <p>(Phase II)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0006"> <li> <p>4 mg/day b.i.d</p> </li> <li> <p>6 mg/day b.i.d</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0002" title="AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ForetteF , AnandR , GharabawiG . A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). European Journal of Neurology1999;6:423‐9. ">B104</a> </p> <p>(Phase II)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.2 (7.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.5 (3.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Belgium, France, UK, Norway, Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0007"> <li> <p>6 to 12 mg/day b.i.d.</p> </li> <li> <p>6 to 12 mg/day t.i.d</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] ">B303/B305</a>* </p> <p>(Phase III)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.0 (8.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0 (4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>France, Germany, Austria, Switzerland, Canada, USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0008"> <li> <p>1 to 4 mg b.i.d</p> </li> <li> <p>6 to 12 mg/day b.i.d., placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0004" title="FeldmanHH , LaneR . Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry2007;78(10):1056‐63. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B304</a>* </p> <p>(Phase III)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.4 (8.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.5 (4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK, Ireland, Australia, Canada, RSA, Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0009"> <li> <p>2 to 12 mg/day b.i.d.</p> </li> <li> <p>2 to 12 mg/day t.i.d.</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a>* </p> <p>(Phase III)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.1 (8.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.0 (4.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0010"> <li> <p>3 mg/day t.i.d</p> </li> <li> <p>6 mg/day t.i.d</p> </li> <li> <p>9 mg/day b.i.d</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a>* </p> <p>(Phase III)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.5 (7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7 (4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0011"> <li> <p>1 to 4 mg per day b.i.d</p> </li> <li> <p>6 to 12 mg/day b.i.d.</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.8 (7.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0012"> <li> <p>6 to 12 mg/day b.i.d</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0013"> <li> <p>6 to 12 mg/day b.i.d.</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0014"> <li> <p>6 to 12 mg/day b.i.d.</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.1 (4.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0015"> <li> <p>6 to 12 mg/day b.i.d.</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Taiwan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0016"> <li> <p>3 to 6 mg/day b.i.d.</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Oral and patches</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a>* </p> <p>(Phase III)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.3 (7.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.5 (3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>North, Central and South America, Asia, Europe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0017"> <li> <p>patch 9.5 mg/day</p> </li> <li> <p>patch 17.4 mg/day</p> </li> <li> <p>capsules 6 to 12 mg/day b.i.d.</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Patches</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>859</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.6 (7.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.6 (3.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>multicentre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ol id="CD001191-list-0018"> <li> <p>patch 4.6 mg/day</p> </li> <li> <p>patch 9.5 mg/day</p> </li> <li> <p>placebo</p> </li> </ol> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>* These studies met the inclusion criteria of the main analysis comparing rivastigmine at the therapeutic doses versus placebo. </p> <p>b.i.d = bis in die in Latin, this means that a medication is taken two times a day, dividing the total daily dose into two doses. </p> <p>t.i.d = ter in die in Latin, this means that a medication is taken three times a day, dividing the total daily dose into three doses. </p> <p>MMSE = Mini‐Mental Health State Examination. The score range from 0 ( severe impairment) to 30 (normal). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of the included studies at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001191-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Objectives of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Objective</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0001" title="AgidY , Dubois B on behalf of the International Rivastigmine Investigators, AnandR , GharabawiG . Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutic Research1998;59(12):837‐45. AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. "><b>B103</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To assess the short term (3 months) symptomatic efficacy and tolerability of rivastigmine 4 and 6 mg/day compared with placebo in patients with AD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001191-bbs2-0002" title="AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ForetteF , AnandR , GharabawiG . A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). European Journal of Neurology1999;6:423‐9. "><b>B104</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary: to determine the maximum tolerated dose (MTD) of rivastigmine in patients with mild to moderate dementia of the Alzheimer type (DAT) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Secondary: to determine ‐ a) whether tolerability is different when the drug is administered twice daily (b.i.d.) or three times daily (t.i.d.) ‐ b) if nausea and vomiting, associated with cholinesterase inhibition, can be controlled with antiemetics thereby increasing the MTD, and ‐ c) to assess the efficacy of rivastigmine at its MTD in comparison with that of placebo in the treatment of DAT </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] "><b>B303/B305</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary 1: to evaluate the efficacy of two non‐overlapping dose ranges of rivastigmine (1 to 4mg daily and 6 to 12 mg daily) versus placebo over a 26 week treatment period as assessed by two primary measures of outcome; change from baseline in ADAS‐Cog score and the CIBIC‐Plus score at week 26 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary 2: to evaluate the safety of the study medication as assessed by incidence of adverse events, clinical laboratory evaluations , vital signs, ECG recordings, and the results of physical examination made at baseline and throughout the study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Secondary: to assess dose‐efficacy and dose‐safety relationships for rivastigmine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001191-bbs2-0004" title="FeldmanHH , LaneR . Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry2007;78(10):1056‐63. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. "><b>B304</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary: to evaluate the efficacy and safety of individual highest well‐tolerated doses (range 6 to 12 mg daily) of rivastigmine given b.i.d. or t.i.d. for 26 weeks compared with placebo in the therapy of patients with probable Alzheimer's disease </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Secondary: to compare the twice daily and three times daily dosing regimens with respect to efficacy and safety to evaluate changes in activities of daily living (ADL) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. "><b>B351</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary: to evaluate the efficacy and safety of three fixed doses of rivastigmine (3, 6 and 9 mg/day) and placebo for 26 weeks of treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Secondary: to assess the dose‐efficacy and dose‐safety relationships for rivastigmine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary: to explore the pharmacokinetics of rivastigmine at doses of 3, 6 and 9 mg daily </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] "><b>B352</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary: to evaluate the efficacy and safety of two non‐overlapping dose ranges of rivastigmine (1 to 4 mg daily and 6 to 12 mg daily) and placebo for 26 weeks of treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Secondary: to assess the dose‐efficacy and dose‐safety relationships of rivastigmine. To investigate the relationship between plasma concentrations of rivastigmine and efficacy and safety </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tertiary: to explore the pharmacokinetics of rivastigmine at doses of 1 to 4 and 6 to 12 mg daily </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. "><b>IDEAL</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To compare the efficacy,safety and tolerability of a novel rivastigmine transdermal patch with conventional rivastigmine capsules and placebo in patients with AD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. "><b>Karaman 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To evaluate the efficacy of rivastigmine for a period of 12 months in patients with advanced moderate AD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. "><b>Lopez‐Pousa 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To evaluate the safety and efficacy of rivastigmine in patients with more advanced AD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. "><b>Mowla 2007</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To assess the effect of serotonin augmentation on cognition and ADL of patients with AD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. "><b>Ballard 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To determine whether rivastigmine was better than placebo for agitation and cognition</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] "><b>Tai 2000</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To evaluate the safety and efficacy of Exelon compared with placebo in patients with probable Alzheimer's disease who had dementia ranging from mild to moderate degree </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. "><b>Nakamura 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>To evaluate the efficacy, safety, and tolerability of the 5 cm<sup>2</sup> (9 mg loading dose, 4.6 mg/24 h delivery rate) and 10 cm<sup>2</sup> (18 mg loading dose, 9.5 mg/day delivery rate) rivastigmine patch in Japanese patients with AD </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Objectives of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001191-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Mean daily dose (mg/day) of rivastigmine achieved in the studies at different time points</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>treatment group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0001" title="AgidY , Dubois B on behalf of the International Rivastigmine Investigators, AnandR , GharabawiG . Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutic Research1998;59(12):837‐45. AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. "><b>B103</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0002" title="AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ForetteF , AnandR , GharabawiG . A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). European Journal of Neurology1999;6:423‐9. "><b>B104</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] "><b>B303/B305</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0004" title="FeldmanHH , LaneR . Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry2007;78(10):1056‐63. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. "><b>B304</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. "><b>B351</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] "><b>B352</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. "><b>IDEAL</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. "><b>Karaman 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. "><b>Lopez‐Pousa 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. "><b>Nakamura 2011</b> </a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 to 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>low b.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>medium b.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high b.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high t.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>low b.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>medium b.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high b.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high t.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>low patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>medium patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>medium patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high b.i.d.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="12"> <div class="table-footnote"> <p>Exact doses not available for <a href="./references#CD001191-bbs2-0001" title="AgidY , Dubois B on behalf of the International Rivastigmine Investigators, AnandR , GharabawiG . Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutic Research1998;59(12):837‐45. AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ">B103</a>, <a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a>, <a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a>, <a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Mean daily dose (mg/day) of rivastigmine achieved in the studies at different time points</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001191-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Measured outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Cognitive function</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Activities of daily lIving</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Behavioural symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Physician rated global impression of change</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Other domains</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ADAS‐Cog</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MMSE</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Others</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PDS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Others</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CIBIC‐Plus</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Others</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0001" title="AgidY , Dubois B on behalf of the International Rivastigmine Investigators, AnandR , GharabawiG . Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Current Therapeutic Research1998;59(12):837‐45. AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ">B103</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OE, TMT, NOSGER, DSST, VRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0002" title="AnandR , GharabawiG , EnzA . Efficacy and safety results of the early phase studies with Exelon (ENA‐713) in Alzheimer's Disease: an overview. Journal of Drug Development and Clinical Practice1996;8(2):109‐16. ForetteF , AnandR , GharabawiG . A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). European Journal of Neurology1999;6:423‐9. ">B104</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wechsler psychometric tests, NOSGER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] ">B303/B305</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAS‐CogA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0004" title="FeldmanHH , LaneR . Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry2007;78(10):1056‐63. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B304</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAS‐CogA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAS‐CogA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADAS‐CogA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0007" title="BallardC , Margallo‐LanaM , JuszczakE , DouglasS , SwannA , ThomasA , et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ2005;330:874. ">Ballard 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMAI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0009" title="KaramanY , ErdoganF , KoseogluE , TuranT , ErsoyAO . A 12‐month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2005;19(1):51‐6. ">Karaman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACDS‐ADL, DAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0008" title="AlvaG , GrossbergG , SchmittF , OlinJ . Influence of rivastigmine on activities of daily living: item responder analyses targeting improvement and atability. Annals of Neurology2009; Vol. 66:S49. AlvaG , GrossbergGT , SchmittFA , MengX , OlinJT . Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 4:356‐63. BlesaR , BallardC , OrgogozoJM , LaneR , ThomasSK . Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer's disease. Neurology2007;69(4 Suppl 1):S23‐8. CummingsJ , WinbladB . A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Review on Neurotherapeutics2007;7(11):1457‐63. CummingsJL , FarlowMR , MengX , TekinS , OlinJT . Rivastigmine transdermal patch skin tolerability: results of a 1‐year clinical trial in patients with mild‐to‐moderate Alzheimer's disease. Clinical Drug Investigation2010; Vol. 30, issue 1:41‐9. CummingsJL , FerrisSH , FarlowMR , OlinJT , MengXY . Effects of rivastigmine transdermal patch and capsule on aspects of Clinical Global Impression of Change in Alzheimer's disease: a retrospective analysis. Dementia and Geriatric Cognitive Disorders2010; Vol. 29, issue 5:406‐12. FarlowM , CummingsJ , OlinJ . Conference publication. American Journal of Geriatric Psychiatry. Conference: AAGP Annual Meeting 2009 Honolulu, HI United States. Conference Start: 20090305 Conference End: 20090308. Conference Publication2009; Vol. 17:A58‐9. FarlowMR , GrossbergGT , MengX , OlinJ , SomogyiM . Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry2011; Vol. 26, issue 12:1236‐43. GrossbergGT , OlinJT , SomogyiM , MengX . Dose effects associated with rivastigmine transdermal patch in patients with mild‐to‐moderate Alzheimer's disease. International Journal of Clinical Practice2011; Vol. 65, issue 4:465‐71. GrossbergGT , SchmittFA , MengX , TekinS , OlinJ . Reviews: effects of transdermal rivastigmine on ADAS‐Cog items in mild‐to‐moderate Alzheimers disease. American Journal of Alzheimer's Disease and Other Dementias2010; Vol. 25, issue 8:627‐33. LeeJH , SevignyJ . Effects of body weight on tolerability of rivastigmine transdermal patch: a post‐hoc analysis of a double‐blind trial in patients with Alzheimer disease. Alzheimer Disease and Associated Disorders2011; Vol. 25, issue 1:58‐62. OrgogozoJ‐M . Clinical studies investigating dose‐related outcomes of cholinesterase inhibition with rivastigmine patch. European Journal of Neurology2012; Vol. Conference: 16th Congress of the European Federation of Neurological Societies, EFNS Stockholm Sweden. Conference Start: 20120908 Conference End: 20120911. Conference Publication:, issue var.pagings. WinbladB , CummingsJ , AndreasenN , GrossbergG , OnofrjM , SadowskyC , et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease ‐ rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry2007;22(5):456‐67. WinbladB , GrossbergG , FrolichL , FarlowM , ZechnerS , NagelJ , LaneR . IDEAL: a 6‐month, double‐blind, placebo‐controlled study of the first skin patch for Alzheimer's disease. Neurology2007;69(4 Suppl 1):S14‐S22. WinbladB , KawataAK , BeusterienKM , THomasSK , WimoA , LaneR , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry2007;22(5):485‐91. ">IDEAL</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CLOCK DRAWING, TMT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACDS‐ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADCS‐CGIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0010" title="Lopez‐PousaS . Pilot, multicenter, randomized, double‐blind, controlled, parallel efficacy and safety study of rivastigmine vs placebo in the treatment of cognitive and non‐cognitive symptoms in patients with moderate‐to‐severe Alzheimer's disease. IFPMA Register2005. ">Lopez‐Pousa 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIB, BLESSED DEMENTIA SCALE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ACDS‐ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI‐10, NPI‐4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> <p>ADCS‐CGIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0011" title="MowlaA , MosavinasabM , HaghshenasH , HaghighiAB . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double‐blind, placebo‐controlled clinical trial. Journal of Clinical Psychopharmacology2007;27(5):484‐7. ">Mowla 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WMS‐III,</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CGI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hamilton score</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0013" title="TaiCT , LiuCK , SungSM , PaiMC , HsuCY . The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26‐week study in Taiwan. International Journal of Neuropsychopharmacology2000;3 Suppl 1:S356. [MEDLINE: SR‐HANDSRCH] ">Tai 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001191-bbs2-0012" title="NakamuraY , ImaiY , ShigetaM , GrafA , ShirahaseT , KimH , et al. A 24‐week, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra2011; Vol. 1, issue 1:163‐79. ">Nakamura 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MENFIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BEHAVE‐AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>x indicated that the study measured this outcome.</p> <p>The full names of these scales and their properties are described in <a href="#CD001191-sec-0028">Types of outcome measures</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Measured outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001191-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Comparison of different methods of dealing with missing values</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>rivastigmine n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>placebo n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>result</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>probability level</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>95% confidence limits</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>1 to 4 mg daily versus placebo, ADAS‐Cog measured as change from baseline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.87, 0.25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.08, 0.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐0.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.96, 0.23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.66, ‐0.48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.86, ‐0.52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.99, ‐0.67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐0.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.48, ‐0.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐0.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.72, ‐0.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.80, ‐0.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>6 to 12 mg daily versus placebo, ADAS‐Cog measured as change from baseline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.96, ‐1.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.33, ‐1.27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>967</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.89, ‐0.88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>6 to 12 mg daily versus placebo, ADAS‐Cog measured as change from baseline</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐1.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.30,‐ 1.29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐2.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.96, ‐1.76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐2.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.69, ‐1.55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐2.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.65, ‐1.54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐2.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.29, ‐1.94</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine WMD ‐2.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.00001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.03, ‐1.74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>1 to 4 mg daily versus placebo, CIBIC‐Plus measured as no change or worse</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72, 1.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72, 1.23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72, 1.22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75, 1.26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours placebo</p> <p>Peto OR 1.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80, 1.37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours placebo</p> <p>Peto OR 1.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78, 1.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55, 0.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50, 0.89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52, 0.91</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>1 to 4 mg daily versus placebo, CIBIC‐Plus measured as no change or worse</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60, 0.92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>831</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58, 0.91</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>952</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60, 0.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>18 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65, 1.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>741</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57, 0.91</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62, 0.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55, 0.85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49, 0.81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RDO + OC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>favours rivastigmine</p> <p>Peto OR 0.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51, 0.82</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The results for two outcomes, ADAS‐Cog and CBIC at 12, 18 and 26 weeks, have been pooled for 3 studies, <a href="./references#CD001191-bbs2-0003" title="AnandR , HartmanR , GrahamS . Effects of Alzheimer's disease severity on activities of daily living with long‐term rivastigmine treatment. Journal of the American Geriatrics Society2001;49(4):S151. AnandR , MessinaJ , VeachJ , HartmanR . Effects of rivastigmine in patients with moderately severe Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:199. BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Potential long‐term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains. International Journal of Clinical Practice2003;57(9):756‐60. ErkinjunttiT , SkoogI , LaneR , AndrewsC . Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. International Journal of Clinical Practice2002;56(10):791‐6. FarlowM , AnandR , MessinaJ , HartmanR . Increased cognitive efficacy of rivastigmine in patients with moderate to severe Alzheimer's disease with co‐existing vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:206. FarlowM , MessinaJ , AnandR , HartmanR , VeachJ . Dose dependent effect of rivastigmine on progression of cognitive deterioration in Alzheimer's disease. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. HebertM . [Alzheimer disease: efficacy and tolerance of rivastigmine] [Maladie d'Alzheimer: efficacite et tolerance de la rivastigmine]. Presse Medicale1999;28(32):1757‐8. KumarV , MessinaJ , HartmanR , AnandR . Long‐term cognitive benefits of rivastigmine in Alzheimer's disease patients with vascular risk. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; April 5‐8, 2000; Stockholm, Sweden. 2000:215. LindesayJ . An open label one‐year extension of SDZ‐ENA‐713 studies B303, B304 and B305 to prospectively evaluate long‐term safety, tolerability and efficacy of SDZ‐ENA‐713 in out‐patients with probable Alzheimer's disease. National Research Register2000. RoeslerM , RetzW , Retz JungingerP , DennlerHJ . Effect of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. RöslerM . Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum]. BMJ2001; Vol. 322, issue 7300:1456. RöslerM , AnandR , Cicin‐SainA , GauthierS , AgidY , Dal‐BiancoP , et al on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ1999;318(7184):633‐8. RöslerM , DennlerH , RetzW , GastparW . A double‐blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT). Pharmacopsychiatry1997;30:212. [MEDLINE: SR‐HANDSRCH] RöslerM , RetzW , Retz JungingerP , DennlerHJ . Effects of two‐year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behavioural‐Neurology1998;11(4):211‐6. VincentS , AndrewsC , LaneR . Rivastigmine shows particular efficacy in Alzheimer patients with concomitant hypertension. Proceedings of the 7th International Geneva/Springfield Symposium on Advances in Alzheimer therapy, 2002 Apr 3‐6, Geneva. 2002:253. WilkinsonDG . Rivastigmine was effective and safe in Alzheimer disease. ACP Journal Club1999;131(2):34. [MEDLINE: Cinahl] ">B303/B305</a>, <a href="./references#CD001191-bbs2-0005" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. Novartis . No title. Unpublished. Data provided by Novartis. No year. NovartisPharmaceuticals . ADENA Programme. Unpublished Data1998. ">B351</a>. <a href="./references#CD001191-bbs2-0006" title="BurnsA , SpiegelR , QuargP . Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(3):243‐9. Corey‐BloomJ , AnandR , Veach J for ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology1998;1:55‐65. DoraiswamyM . The effects of rivastigmine on the Alzheimer's disease assessment scale‐cognitive subscale items scores of patients with Alzheimer's disease. Health in aging the challenge and promise of new decade. Proceedings of the annual scientific meeting of the American Geriatrics Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:173. DoraiswamyPM , AnandR , HartmanR . Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately‐severe to severe AD. Clinical Neuropschological Assessment2000;1(6):12. DoraiswamyPM , AnandR , HartmanR . Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine. Clinical Neuropschological Assessment2000;1(6):14. FarlowM , HakeA , MessinaJ , VeachJ , AnandR . The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression. Neurology2000; Vol. 54 Suppl 3:A469. FarlowM , MessinaJ , AnandR . Long term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease results following two years of treatment. Proceedings of the Annual Scientific Meeting of the American Geriatric Society and the American Federation for Aging Research; 2000 May 17‐21, Nashville. 2000:172. FarlowM , PotkinS , KoumarasB , VeachJ , MirskiD . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26‐week, Alzheimer disease trial. Archives of Neurology2003;60:843‐8. FarlowMR , HakeA , MessinaJ , HartmanR , VeachJ , AnandR . Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Archives of Neurology2001;58(3):417‐22. FerrisS . Improving day to day functioning in patients with AD. Proceedings of the Ninth Congress of the International Psychogeriatric Association; 1999 Aug 15‐20, Vancouver. 1999:77. KrishnanKR , DorasiswamyPM , MessinaJ , VeachJ , ENA 713 B352 Study Group. Rivastigmine slows stage specific global deterioration in Alzheimer's disease. Journal of the American Geriatrics Society1999;47:S3. KumarV , AnandR , MessinaJ , HartmanR , VeachJ . An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology2000;7(2):159‐69. VeachKR , DoraiswamyPM . Rivastigmine slows stage‐specific global deterioration in Alzheimer's disease. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20, Washington DC. 1999. [MEDLINE: SR‐HANDSRCH] ">B352</a>. These studies reported results for 3 populations, intention‐to‐treat (ITT), completers (OC), and completers + retrieved dropout (RDO + OC). The table reports the results of the meta‐analyses for 2 comparisons (1 to 4 mg daily versus placebo and 6 to 12 mg/day versus placebo) for the 3 populations at the 3 time points. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Comparison of different methods of dealing with missing values</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/full#CD001191-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001191-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm2 (9.5 mg/day) patch) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ADAS‐Cog (change from baseline at 24‐26 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.79 [‐2.21, ‐1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 MMSE (change from baseline at 24‐26 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.52, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Activities of daily living (change from baseline at 24‐26 weeks ) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.13, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinical Global Impression (no change or worse at 24‐26 weeks ) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.58, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Behavioural symptoms (change from baseline at 24‐26 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.14, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawals before end of treatment at 24‐26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.74, 2.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 at least one adverse event by 24‐26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [1.82, 2.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 NPI‐D carer distress scale (change from baseline at 24‐26 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.91, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Rivastigmine (capsules 6 to 12 mg/day in two divided doses or 10 cm2 (9.5 mg/day) patch) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001191-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ADAS‐Cog (change from baseline at 12 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 rivastigmine (1‐4 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.87, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.49 [‐1.96, ‐1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 ADAS‐Cog (change from baseline at 26 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 rivastigmine (1‐4 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.84 [‐1.48, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.99 [‐2.49, ‐1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 MMSE (change from baseline at 26 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 rivastigmine (1‐4 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.08, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.56, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 SIB (change from baseline at 26 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Rivastigmine 6‐12 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.53 [0.47, 8.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 ADCS‐ADL (change from baseline at 26 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.20, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 PDS (change from baseline at 12 weeks ) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 rivastigmine (1‐4 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.77 [‐1.84, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.19, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 PDS (change from baseline at 26 weeks ) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 rivastigmine (1‐4 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐1.61, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [1.13, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Clinical Global Impression (no change or worse at 12 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 rivastigmine (1‐4 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.72, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.60, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Clinical Global Impression (no change or worse at 26 weeks ) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 rivastigmine (1‐4 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.55, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.55, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 GDS( moderately severe, severe, or very severe dementia at 26 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 rivastigmine (1‐4 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.71, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1923</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.64, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 CGIC (little or no improvement, or worse at 12 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 rivastigmine (1‐4 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.60, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.43, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Behavioural disturbance NPI‐10 or NPI‐12 (change from baseline at 26 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Rivastigmine (6‐12 mg/day) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.20, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 withdrawals before end of treatment at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 rivastigmine (1‐4 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.95, 4.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [1.19, 5.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 withdrawals before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 rivastigmine (1‐4 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.75, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [1.83, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 at least one adverse event by the end of titration period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 rivastigmine (1‐4 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.82, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.96 [2.39, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 at least one adverse event by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.71, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [2.05, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 dropouts due to adverse events by 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 rivastigmine (4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [1.06, 6.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 rivastigmine (6mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.11 [1.28, 7.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 dropouts due to adverse events by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 rivastigmine (1‐4 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.69, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [2.19, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 at least one adverse event of decreased appetite by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.51 [1.26, 9.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 at least one adverse event of weight decrease by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.55 [1.46, 8.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 at least one adverse event of nausea by the end of titration period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.36, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.57 [4.59, 6.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 at least one adverse event of nausea by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.28, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 rivastigmine (6‐12mg/d bid) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.36 [4.50, 6.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 at least one adverse event of vomiting by the end of titration period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [1.22, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.72 [4.48, 7.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 at least one adverse event of vomiting by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.08, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.15 [4.20, 6.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 at least one adverse event of diarrhoea by the end of titration period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.68, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [1.51, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 at least one adverse event of diarrhoea by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.67, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.39, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 at least one adverse event of anorexia by the end of titration period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.24, 3.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.94 [3.56, 6.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 at least one adverse event of anorexia by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [1.29, 3.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.46 [3.34, 5.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 at least one adverse event of headache by the end of titration period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.69, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.26, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 at least one adverse event of headache by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.84, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [1.34, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 at least one adverse event of insomnia by the end of titration period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.64, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.94, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 at least one adverse event of insomnia by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.70, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.95, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 at least one adverse event of syncope by the end of titration period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.43, 5.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.99, 4.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 at least one adverse event of syncope by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.37, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 rivastigmine (6‐12mg/d bid) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.96, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 at least one adverse event of abdominal pain by the end of titration period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.72, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [1.80, 3.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 at least one adverse event of abdominal pain by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.77, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [1.65, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 at least one adverse event of dizziness by the end of titration period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.70, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [1.86, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 at least one adverse event of dizziness by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.91, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [1.78, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 at least one adverse event of bone fracture by the end of titration period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.25, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.37, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 at least one adverse event of bone fracture by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.27, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.34, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 at least one adverse event of asthenia by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.37 [1.79, 10.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 at least one severe adverse event by the end of titration period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.62, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [1.39, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 at least one serious adverse event by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.70, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.93, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 deaths before end of treatment at 12 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.34 [0.76, 71.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.2 rivastigmine (6‐12 mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.45 [0.46, 119.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 deaths before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.20, 19.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.40, 3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 CIBIC‐Plus (no change or worse at 12 weeks) OC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.58, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47 CIBIC‐Plus (no change or worse at 26 weeks) OC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.50, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.49, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48 CIBIC‐Plus (no change or worse at 12 weeks) OC+RDO <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.72, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.60, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49 CIBIC‐Plus (no change or worse at 26 weeks)OC+RDO <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1093</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.52, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.51, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50 CIBIC‐Plus (no change or worse at 12 weeks) ALL+OC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.77, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.72, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51 CIBIC‐Plus (no change or worse at 26 weeks) ALL+OC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.55, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.69, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52 ADAS‐Cog (change from baseline at 12 weeks) OC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐1.08, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐2.33, ‐1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53 ADAS‐Cog (change from baseline at 26 weeks) OC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1045</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.97 [‐1.72, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.62 [‐3.29, ‐1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54 ADAS‐Cog (change from baseline at 12 weeks) OC+RDO <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.96, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1795</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.38 [‐1.89, ‐0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55 ADAS‐Cog (change from baseline at 26 weeks) OC+RDO <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.1 rivastigmine (1‐4mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.07 [‐1.80, ‐0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.2 rivastigmine (6‐12mg/d) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.39 [‐3.03, ‐1.74]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Rivastigmine oral capsules (1 to 4 mg/day or 6 to 12 mg/day in two divided doses) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001191-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ADAS‐Cog (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.6 [‐3.72, ‐1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 TMT‐A (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.2 [‐24.11, ‐4.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 clock drawing (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [‐0.34, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 MMSE (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.32, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 ADCS‐ADL (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.3 [0.52, 4.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 NPI‐12 (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐2.88, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 withdrawals before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [1.22, 2.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 at least one adverse event by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [1.64, 3.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 withdrawals due to an adverse event before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.93, 3.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 at least one adverse event of dizziness by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.14 [1.31, 7.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 at least one adverse event of nausea by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.12 [2.85, 9.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 at least one adverse event of vomiting by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.77 [3.38, 13.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 at least one adverse event of weight decrease by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.12 [2.09, 17.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 at least one adverse event of decreased appetite by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.19 [1.49, 18.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 at least one adverse event of headache by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.66 [0.94, 7.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 at least one adverse event of asthenia by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [0.82, 11.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 deaths before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.40, 7.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 NPI‐D carer distress scale (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.07, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Rivastigmine 20 cm2 patch (17.4 mg/day) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001191-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ADAS‐Cog (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.35 [‐2.03, ‐0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 MMSE (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.26, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 clock drawing (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [‐0.17, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 TMT‐A (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.0 [‐29.80, ‐10.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental Function Impairment MENFIS (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐2.32, ‐0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 ADCS‐ADL (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.20 [0.62, 3.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Disability Assessment for Dementia (DAD) (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [0.34, 4.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 BEHAVE‐AD (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.92, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 NPI‐12 (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐2.16, 2.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Clinical Global Impression (no change or worse at 24 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.58, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 withdrawals before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.23, 2.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 at least one adverse event by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.29, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 withdrawals due to an adverse event before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.20, 2.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 at least one adverse event of application site erythema by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [1.87, 3.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 at least one adverse event of application site pruritis by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [1.36, 2.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 at least one adverse event of application site edema by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.83 [2.09, 11.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 at least one adverse event application site exfoliation by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [0.88, 8.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 at least one adverse event of dermatitis contact by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [1.24, 2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 at least one adverse event of nasopharyngitis by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.62, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 at least one adverse event of nausea by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.07, 3.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 at least one adverse event of vomiting by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.20, 3.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 at least one adverse event of diarrhoea by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.87, 4.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 at least one adverse event of weight decrease by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [0.63, 7.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 at least one adverse event of dizziness by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.36, 3.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 at least one adverse event of decreased appetite by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.11, 4.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 at least one adverse event of headache by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [0.71, 6.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 at least one adverse event of asthenia by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.41, 7.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 deaths before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.28, 3.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 NPI‐D carer distress scale (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.91, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Rivastigmine 10 cm2 patch (9.5 mg/day) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001191-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ADAS‐J Cog (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.8 [‐1.62, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 MMSE (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.52, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental Function Impairment MENFIS (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.72, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Disability Assessment for Dementia (DAD) (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐0.73, 3.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 CIBIC‐Plus J (no change or worse at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.43, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 BEHAVE‐AD (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.67, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 withdrawals before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.01, 2.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 at least one adverse event by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.16, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 withdrawals due to an adverse event before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.12, 3.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 at least one adverse event of application site erythema by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [1.73, 3.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 at least one adverse event of application site pruritis by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.23, 2.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 at least one adverse event of application site edema by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.65 [2.46, 12.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 at least one adverse event application site exfoliation by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.68 [1.20, 11.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 at least one adverse event of dermatitis contact by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.30, 3.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 at least one adverse event of nasopharyngitis by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.38, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 at least one adverse event of nausea by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.09, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 at least one adverse event of vomiting by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.43, 2.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 deaths before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.06, 16.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Rivastigmine 5 cm2 patch (4.6 mg/day) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001191-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ADAS‐Cog (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐1.10, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 MMSE (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.27, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 clock drawing (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.46, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 TMT‐A (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐13.48, 8.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 ADCS‐ADL (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐1.23, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Clinical Global Impression (no change or worse at 24 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.88, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 NPI‐12 (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐1.55, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 withdrawals before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.70, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 at least one adverse event by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.43, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 withdrawals due to an adverse event before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.68, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 at least one adverse event of nausea by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.15, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 at least one adverse event of vomiting by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.18, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 at least one adverse event of diarrhoea by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.57, 2.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 at least one adverse event of weight decrease by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.21, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 at least one adverse event of dizziness by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.13, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 at least one adverse event of decreased appetite by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.04, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 at least one adverse event of headache by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.25, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 at least one adverse event of asthenia by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.10, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 deaths before end of treatment at 24 weeks + 30 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.56 [0.49, 13.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 NPI‐D carer distress scale (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.96, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Rivastigmine 10 cm2 patch (9.5 mg/day) versus rivastigmine capsules (6 to 12 mg/day in two divided doses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001191.pub4/references#CD001191-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001191.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001191-note-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001191-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001191-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD001191-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001191-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001191\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001191\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001191\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001191\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001191\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=EBp84H4P&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001191.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001191.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001191.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001191.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001191.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728700450"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001191.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728700454"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001191.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ecae16e8cf56f',t:'MTc0MDcyODcwMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 